% #&  



         

  
   ! "
!  " 
#" $'(')
!$*++,,,"+$$-+,'(')
  %   
./)/ --!0-- 10
2 3  /4.('
506 


                 !"#$!%
& &' (&   )  '   )*+&*'(,#-.#-%/ )   
'  &  0*,"!1#%20      &         )3
      45 25          
 / *36)7 3+738 393:9 3( &8 3
07      *  5 3+*7  4 7345 3-!!!; 
')      3+ <) 0=3: )  >  3
 -!!!//)(' 3     *)0    ? 7 ,,"2 7 3
&; 3/ /           @ 3& '    
      2&'A   2(7    &  
/           2(         
  2( B              *   )  
2
C-!!273& 02& &92 2 2/      B 3
B   3D    B          3 C 3
 2

-0 ! 1 7"2 "7 "1 - "7  ! 1
  3    ! "  !  " 
% #" $ " '(')
506 4//.
5 " 443 ..3 ..
$%#%

 2!" ""6 - 1"$  $$ " "2$ ! $7"2 "7 $06 70  $"1  2 7" "!" 0-   ! 2!" ""6 -2-  # $"-- !
2- ! 0" "7 "2$ 2-3 ,! ", 7" 6 77-  !
771-- "7 23 -  - 7" "2$" "7 23 $ "3  ! !-"7 $ $"$0"- "63 ! # $"-- 2"  -$6  7- 6 78 77- !
- 77-  ! 771-- "7 2 9:2 77-;<3  77- ! -
77-  ! 0"-1 !-- "7 $- 9:$"$0" 77-;< ! -2 2" 
- !6$"! "2$-"- "7 !", 77 - ,"0  ! -2 $"$0"- ! $"6
8$2 "7 -7 ! 2 $- "7 2" "-=771 - -0-- ! 
"0 !1 -76  0 2 "-- ,!"0 "2$"2- !! "0"2- 6  76
 -7 - $-

  
1-6 "7 7" "-  %
   ! "
1-  "-      -0 >- ""2" 9<
!  " 
"02 1-6

1

1

Introduction

Relative performance evaluations provide incentives to workers and managers, identify best
practices in organizations, and inform resource allocation decisions. In light of these merits, the neglected problem of implementing meaningful relative performance measurements is
important. In this paper, we address the practical problem of comparing the performance of
similar activities that are not directly comparable. Our speciâ€¦c application is the provision
of alcohol-abuse treatment in the state of Maine (USA). Essentially, we develop a methodology for â€œbenchmarkingâ€ the performance of these health service providers, and apply this
methodology to estimate potential eÂ¢ciency gains from identifying and transferring â€œbest
practicesâ€.
As a general motivation for our analysis, consider the following stylized problem. Suppose
a decision-maker is interested in comparing the cost-eÂ¤ectiveness of N independent service
units. The decision-maker observes costs and an output measure for each unit. However, the
naive use of these data to compare productivities is problematic because the units produce
diÂ¤erentiated services. Such diÂ¢culties of relative performance evaluation are particularly
apparent for health care services.

First, the activities of the service units may not be

directly comparable because each is treating a diÂ¤erent patient population. A unit may
perform worse simply because of a more diÂ¢cult case load. Second, the service units may be
hard to compare because their activities diÂ¤er in quality. For example, the outcome measure
might be a measure of morbidity immediately following a hospital procedure. The discharged
patients of a hospital with low measured morbidity might suÂ¤er future complications or have
low survival rates. Under circumstances like these, how can the decision-maker meaningfully
compare the performance of the N service units?

2
We confront the real life diÂ¢culties of comparing the performance of publicly-funded
substance abuse treatment providers in the state of Maine in the United States. Maineâ€™s
OÂ¢ce of Substance Abuse (OSA) in the 1980â€™s and 90â€™s allocated public funds to qualiâ€¦ed
substance-abuse treatment programs. OSA thought that some of these programs might be
better than others at remedying drug and alcohol abuse, and collected data in order to
measure and compare their performance. The inputs used in treatment and the costs of
providing treatment were relatively easy to monitor, but the outputs of the treatment agencies were diÂ¢cult to measure directly and diÂ¢cult even to deâ€¦ne precisely. Adding to this
diÂ¢culty, the agencies treated populations living in diÂ¤erent parts of the state. Although
OSA measured characteristics of these diÂ¤erent patient populations, it is likely that there is
important unmeasured heterogeneity in these populations. We develop and apply a methodology for comparing the performance of the diÂ¤erent agencies treating diÂ¤erent populations.
The methodology is based on a model of the treatment processes that is designed to exploit
the information contained in multiple outcome measures. The outcome measures are time
in treatment, completion of treatment, and alcohol use at completion.
To illustrate some of the issues that our methodology addresses, consider Figure 1. The
â€¦gure shows the percentage of admitted patients that successfully completed treatment in
each of the 12 months after admission for three treatment agencies. These completion densities are very diÂ¤erent. For Agency A, the density peaks at 3 months, for B at 6 months,
and for C at 8 months.

Moreover, patients in A and C were noticeably more likely to

complete treatment within twelve months than those at B. There are several possible explanations for Aâ€™s apparently superior performance. First, A might provide superior treatment,
leading to a higher probability of completion compared to B or quicker success compared

3

Figure 1: Sample Completion Densities
to C. Similarly, A might use more intense and therefore more costly treatment to achieve
the better outcomes, e.g. provide patients more hours of treatment per week. Third, Aâ€™s
patients might enter treatment with less severe aÂ­ictions than patients at B and C. Lastly,
A might have less stringent clinical standards for the completion of treatment. Obviously
these diÂ¤erent explanations have diÂ¤erent implications for comparing the cost-eÂ¤ectiveness
of the agencies.
To distinguish these alternative explanations empirically, we model a production process
for a health treatment with the following general properties: (1) production takes time;
(2) production is uncertain; (3) production occurs under varying exogenous conditions; (4)
output is not perfectly observable. More speciâ€¦cally, we model the health treatment process
as illustrated in Figure 2: a patient enters a treatment program with an initial (scalar-valued)
health status (h0 ), health status evolves stochastically through time in response to treatment

4

h

Health
Status

ht

time

Figure 2: Health care treatment process

(ht ), and treatment is completed when the patientâ€™s health status crosses an upper threshold
(h). We model the evolution of ht as a Wiener process, and completion of treatment as the
Â¹ As a result, the time it takes to complete treatment has an
â€¦rst crossing of the barrier h.
Inverse Gaussian distribution.
In order to deal with the measurement problems outlined above, our empirical implementation of the model allows that: (a) diÂ¤erent treatment programs diÂ¤er in their eÂ¤ectiveness
at improving health status; (b) diÂ¤erent programs have diÂ¤erent populations of patients
entering treatment (both with regard to observables and econometric unobservables); and
(c) diÂ¤erent programs have diÂ¤erent thresholds for the completion of treatment. The empirical model also controls for the fact that some patients exit treatment prematurely, and
allows the rate of attrition to vary from program to program. Our estimation methodology
is maximum likelihood, using the Inverse Gaussian distribution for the time to completion

5
of treatment.1 Health status is not directly observable, although the data set includes indicators of health status at admission and discharge. We are careful to control for possible
unobserved heterogeneity and to distinguish â€œtreatment eÂ¤ectsâ€ from unobserved population
characteristics.
Our model is estimated with data drawn from an admission-discharge data set for patients
receiving outpatient treatment for alcohol abuse provided by publicly-funded agencies in the
state of Maine. This is the data that OSA collected to inform its budget allocation problem.
The data set matches patients to treatment agencies. Our analysis indicate that these
agencies diÂ¤er substantially not only in their ability to improve the health of alcohol abusers,
but also in their completion thresholds, the initial health of their patient populations, and
their ability to retain patients until completion of treatment. The estimated model enables
us to simulate the improvement in the health status of any population of patients in any
treatment program. We also separately estimate an equation predicting the quantity of
treatment patients would receive at diÂ¤erent agencies, combine this with unit cost data
drawn from the contracts between the treatment agencies and OSA, and thereby predict the
total cost of treating any population of patients in any treatment program. Our results show
signiâ€¦cant diÂ¤erences in the estimated productivities, i.e. the improvement of health per
dollar spent, of the diÂ¤erent treatment agencies, suggesting the possibility of eÂ¢ciency gains
if the less productive agencies were to adopt the â€œtechnologiesâ€ (e.g. practice styles and
management techniques) of the more eÂ¢cient ones. In practice, such a technology transfer
might be accomplished by mergers, information exchange, or training.
We estimate that a transfer of best practices could reduce treatment costs signiâ€¦cantly
1

See Lancaster (1990) for a discussion of the Wiener process as a duration model.

6
without compromising health outcomes. The nature of our policy experiments is illustrated
in Table 1, which presents estimates (based on our estimated model) of how Maine could
reduce expenditures while not reducing the number of abstinent discharged patients. For
example, by transferring the practice style of Agency 6 to Agency 13â€™s patient population,
Maine could save a signiâ€¦cant $63,260 (standard error in parentheses), and by transferring
the practice style of Agency 12 to Agency 15â€™s population, another $29,091. The total of
such proâ€¦table transfers comes to $203,752, which is 9.27% of the budget of the top â€¦fteen
publicly funded agencies.
The recent literature on treatment eÂ¤ects has emphasized non-parametric or semi-parametric
estimation to obtain robust conclusions (Manksi, 1996), and instrumental variables to control
for endogenous selection (Imbens and Angrist (1994), Heckman (1997)). In our empirical
context, good instruments to control for unobserved patient heterogeneity are not readily
available. Therefore, we follow the structural literature (e.g. Olley and Pakes (1996), Keane
and Wolpin (1997), and Eckstein and Wolpin (1999)) by specifying a model that identiâ€¦es
the parameters of interest. As detailed later, the key identiâ€¦cation restrictions arise very
naturally in our model of the treatment process. Our methodology is most related to that of
Olley and Pakes (1996) who impose reasonable covariance restrictions to estimate a production function with endogenous inputs. In our case, an â€œendogeneity problemâ€ arises because
unobserved patient characteristics might be correlated with patientsâ€™ assignments to treatment agencies.2 In the same spirit as Olley and Pakes (1996), we exploit data on alcohol use
at admission to help control for the resulting endogeneity problem. Finally, our parametric
model has the beneâ€¦t of enabling strong predictions from policy simulations, in particular
the â€œtransfer of best practicesâ€ policy experiment mentioned above.
2

We also â€¦nd direct evidence that patient populations diÂ¤er in their unobserved characteristics.

7

Controlling for Unobservable Population EÂ¤ects
Population of Treated by
Cumulative
Agency
Agency
$ Savings $ Savings
63259:59
13
6
63259:59
(11115:76)
92350:99
15
12
29091:40
(14170:04)
119866:09
7
6
27515:10
(21630:42)
146366:34
10
4
26500:25
(27846:17)
165846:91
3
4
19480:57
(44810:56)
182482:61
14
12
16635:7
(45690:58)
191441:56
8
4
8958:95
(80298:50)
198166:31
11
12
6724:75
(81374:71)
201535:10
9
4
3368:79
(83680:47)
203752:16
1
2
2217:06
(82687:48)
203752:16
6
6
0
(82687:48)
203752:16
5
5
0
(82687:48)
203752:16
4
4
0
(82687:48)
203752:16
12
12
0
(82687:48)
203752:16
2
2
0
(82687:48)

Cumulative
% Savings
0:0288
(0:0049)
0:0420
(0:0063)
0:0546
(0:0097)
0:0666
(0:0126)
0:0755
(0:0205)
0:0831
(0:0209)
0:0871
(0:0367)
0:0902
(0:0372)
0:0917
(0:0382)
0:0927
(0:0378)
0:0927
(0:0378)
0:0927
(0:0378)
0:0927
(0:0378)
0:0927
(0:0378)
0:0927
(0:0378)

Table 1: Cost reducing technology transfers, controlling for population eÂ¤ects in terms of
abstinence

8
The rest of the paper is organized as follows. Section 2 describes our basic model of the
treatment process, and outlines our estimation methodology. Section 3 describes the data
set to which we apply the model; Section 4 discusses the estimated model, applies the model
to compare the performance of diÂ¤erent treatment agencies and estimates the potential gains
from transferring â€œbest practices.â€ Section 5 concludes and outlines some possible directions
for further research. The appendix discusses additional estimation and simulation results
and the health services literature on the eÂ¤ectiveness of substance abuse treatment.

2

Model and estimation strategy

2.1

Time in treatment and health improvement

Consider the following model of health care treatment. A patient i enters treatment with
an initial health status hi0 . Once in treatment, the patientâ€™s health status, hit , evolves
stochastically according to a Wiener process with drift Â¹i and variance Â¾ 2 . If hit crosses an
upper threshold, hi , then the patient is deemed to have completed treatment successfully.
It follows from the distribution theory for Wiener processes that the cumulative probability
distribution of completion times for patient i is the Inverse Gaussian distribution,
F (ti ; Â¹i ; Â¾; Â¢hi ) = 1 Â¡ Â©(

2Â¹i Â¢hi
Â¢hi Â¡ Â¹i t
Â¡Â¢hi Â¡ Â¹i t
p
p
) + e Â¾2 Â©(
)
Â¾ t
Â¾ t

(1)

where Â¢hi = hi Â¡ hi0 is the total change in health necessary for completion, and Â© (Â²) is
the cumulative normal distribution. A simple estimation strategy would be to â€¦t time until
completion of treatment (ti ) to the Inverse Gaussian distribution function by estimating Â¹i ,
Â¾, and Â¢hi as parametric functions of patient characteristics.
A problem with this simple approach is that some patients drop out of treatment before

9
completion. This is problematic because patient attrition is potentially a source of selection
bias.

For example, if less healthy patients are more likely to drop out before completion

of treatment, then those agencies with a â€œslowerâ€ treatment process will have a healthier
population of patients who complete treatment. One way to control for patient selection is as
follows.3 If Â¸i (t) is patient iâ€™s time-varying exogenous dropout hazard, then the distribution
of dropout times for patient i is:
G(ti ; Â¸i (Â¢)) = 1 Â¡ eÂ¡

R ti
0

Â¸i (s)ds

:

(2)

Therefore, if ci is a dummy variable indicating whether the patient has completed treatment,
rather than exiting prematurely, and ti is the patientâ€™s time in treatment, then the likelihood
function for (ci ; ti ) is
ff(ti ; Â¹i ; Â¾; Â¢hi )[1 Â¡ G(ti ; Â¸i (Â¢))]gci Â£ fg(ti ; Â¸i (Â¢))[1 Â¡ F (ti ; Â¹i ; Â¾; Â¢hi ]g1Â¡ci

(3)

where f (Â¢) and g(Â¢) are the density functions derived from F (Â¢) and G(Â¢), respectively. An
empirical implementation of this model might specify Â¹i ; Â¾; Â¸i ; and Â¢hi as parametric functions of patient characteristics and estimate the parameters by maximizing the likelihood
function. This strategy controls for patient attrition by exploiting two outcome measures:
completion of treatment (ci ) and time in treatment.(ti ).4
A limitation of this more sophisticated model is that it does not separately identify the
two components of Â¢hi = hi Â¡ hi0 , and therefore cannot distinguish whether a treatment
program has a higher completion threshold (hi ) or a healthier population at admission (hi0 ).
3

For diÂ¤erent views on how to deal with dropouts in the substance abuse literature see, for example,
Anglin and Hser (1990), Apsler (1991), Apsler and Harding (1991), Ball and Ross (1991), and the Gerstein
and Hardwood (1990).
4
A possibility for further research is to endogenize a patientâ€™s exit decision. For example, a patientâ€™s
decision to leave treatment before completion might be triggered by a disappointing evolution of health
status while in treatment.

10
Separate identiâ€¦cation of these diÂ¤erences is possible if the model is augmented to incorporate additional outcome measures. Assume that there are measures of health observed at
admission to treatment and at completion of treatment: qi0 is observed at admission and
Â­i0 (qi0 jhi0 ) is the probability of qi0 conditional on hi0 ; similarly, q i is observed if the patient
completes treatment (ci = 1),5 and Â­i (q i jqi0 ; hi ; hi0 ) is the conditional probability of qi given
(qi0 ; hi ; hi0 ). Then the likelihood function for (ci ; ti ; qi0 ; qi ) is
ff (ti ; Â¹i ; Â¾; Â¢hi )[1 Â¡ G(ti ; Â¸i (Â¢))]gci Â£ fg(t; Â¸i (Â¢))[1 Â¡ F (ti ; Â¹i ; Â¾; Â¢hi ]g1Â¡ci Â£
Â¹ i (q i jqi0 ; hi ; hi0 )ci
Â­i0 (qi0 jhi0 ) Â£ Â­

(4)

Taking logs and summing over patients gives the log likelihood function for the sample of
patients under the assumption of independent likelihood functions across patients.
Our estimation strategy for the augmented model is to specify hi0 , hi , Â¹i , Â¸i (t), Â­i0 (qi0 jhi0 ),
Â¹ i (qi jqi0 ; hi ; hi0 ) as functions of the data, substitute these functions into the sample log
and Â­
likelihood function, and maximize the resulting function to obtain parameter estimates. Importantly, we allow for an unobserved patient characteristic Âµi . Let a patientâ€™s initial health
be a linear function of patient characteristics observed by the econometrician (vector Xi )
and an unobserved characteristic (Âµi ), i.e.
hi0 = Â®0 Xi + Âµi

(5)

Let Aij denote a dummy variable that is equal to 1 if patient i is assigned to program
j (= 1; :::J), and equal to 0 otherwise, and Ai the vector of these dummy variables for
patient i. We specify the drift, threshold, and log dropout hazard as linear functions of these
5

As is often the case, we have less reliable information on the status of patients who drop out of treatment
than for those who complete treatment.

11
variables:
Â¹i = Â± 0 Xi + Â± 1 Ai + Â± 2 Âµ i

(6)

hi = Â¯ 0 Xi + Â¯ 1 Ai + Â¯ 2 Âµi

(7)

ln Â¸i (t) = Â° 0 Xi + Â° 1 Ai + Â° 2 Âµi + Â° 3 t

(8)

The agency dummies Ai enter these three equations directly. We refer to the coeÂ¢cients
on these dummies as â€œtreatment eÂ¤ects,â€ and interpret them as capturing diÂ¤erences in
practice style across agencies that result in a diÂ¤erent treatment process. This is a quasireduced form approach to estimating treatment eÂ¤ects in the sense that we are not modelling
the underlying decisions that determine these eÂ¤ects. For example, a particular agency might
have a higher than normal drift rate because the agencyâ€™s practice style is to treat patients
more intensely (e.g. schedule more hours of treatment per week). Perhaps the same agency
also has higher attrition rates due to the more demanding schedule.6 Importantly, Ai does
not directly enter the hi0 equation. The reason is clear: hi0 is a variable determined prior to
the treatment process and by deâ€¦nition not subject to treatment eÂ¤ects of the agencies.
If patients were assigned randomly to agencies, then we could treat Âµi as an unobservable
independent of Ai and estimate the treatment eÂ¤ects (Â±1 ; Â¯ 1 ; Â° 1 ). However, since this is not
an experimental setting, it seems presumptuous to assume that Âµi is uncorrelated with Ai .7
6

Later, we relate agency performance to a few characteristics of the agency. An alternative approach
would be to incorporate key agency characteristics directly into the model in lieu of the treatment eÂ¤ect
dummies.
7
In our alcohol abuse treatment setting, this correlation could arise because agency assignment is primarily based on where patients live and patients characteristics might vary geographically. In fact, observed
characteristics Xi are clearly correlated with Ai in our data. As such, it is likely that the unobserved Âµ i is
correlated with Ai .
There are also other possible reasons for correlation between Ai and Âµ i . For example, it is conceivable
that some treatment agencies selectively admit patients based on hi0 . Our model may not perfectly capture
selection where patients are accepted or rejected based on hi0 , since in this case the distribution of Âµi
conditional on Ai and Xi might be truncated. However, we should pick up the mean eÂ¤ect of such selection
in our Â®1 .

12
Accordingly, we assume that the conditional distribution of Âµi given Ai and Xi is normal
with mean Â¼ 1 Xi + Â®1 Ai , i.e.
Âµ i = Â¼ 1 Xi + Â® 1 Ai + " i

(9)

where "i Â» N (0; 1):8 Substituting (9) into (5) - (8) we obtain
hi0 = Â®0 Xi + Â®1 Ai + "i

(10)

Â¹i = Â± 0 Xi + (Â± 1 + Â± 2 Â®1 )Ai + Â±2 "i

(11)

hi = Â¯ 0 Xi + (Â¯ 1 + Â¯ 2 Â®1 )Ai + Â¯ 2 "i

(12)

ln Â¸i (t) = Â° 0 Xi + (Â° 1 + Â° 2 Â®1 )Ai + Â° 2 "i + Â° 3 t

(13)

where the coeÂ¢cients on Xi have been redeâ€¦ned to include Â¼1 :9
Examining (11)-(13), note that there are two eÂ¤ects of Ai on each of Â¹i , hi and Â¸i . The
â€¦rst eÂ¤ect (e.g. the J-vector Â± 1 in (11)) is the â€œtreatment eÂ¤ectâ€ - an attribute of the agency
providing treatment to patient i. The second eÂ¤ect (e.g. the scalar Â±2 times the J-vector
Â®1 ) is the â€œpopulation eÂ¤ectâ€ - capturing the fact that a particular agency has patients with
higher or lower values of the unobservable characteristic.
Separating these treatment eÂ¤ects and population eÂ¤ects is very important for our goal
of comparing performances of diÂ¤erent treatment agencies. We want to â€œrankâ€ agencies
based on the eÂ¤ectiveness of their treatment program (i.e. their treatment eÂ¤ects), and not
8

Setting the variance of "i equal to unity is inoquous because health is a latent variable as it will become
clear shortly. Hence, since hi0 is only â€œobservedâ€ through ordered variables representing frequency of alcohol
use, we need to make this normalization to deâ€¦ne what a â€œunit of healthâ€ is. Note that we are also currently
assuming that the "i is homoscedastic, i.e. its variance does not depend on (Xi ; Ai ).
9
Precisely, the transformations are Â®0 = Â®0 + Â¼1 ; Â± 0 = Â± 0 + Â± 2 Â¼ 1 ; Â¯ 0 = Â¯ 0 + Â¯ 2 Â¼1 , and Â° 0 = Â° 0 + Â° 2 Â¼ 1 .
This simply emphasizes that we cannot separate the direct eÂ¤ect of a particular Xi characteristic and the
eÂ¤ect through that characteristicâ€™s correlation with the unobserved characteristic. This lack of identiâ€¦cation
muddies the interpretation of the coeÂ¢cients on Xi :

13
based on whether they happen to admit patients that are unobservably easier or harder to
treat (i.e. their population eÂ¤ects). Importantly, these treatment and population eÂ¤ects are
separately identiâ€¦ed because, by deâ€¦nition, hi0 does not depend on a treatment eÂ¤ect. The
observed eÂ¤ect of Ai on hi0 gives us a pure view on the population eÂ¤ect which can then be
â€œnettedâ€ out of the other equations.
Moving to our indicators of health at admission and completion, let qi0 and q i be categorical variables with M + 1 possible integer values, indexed m = 0; :::M . We assume that
qi0 and q i are related to hi0 and hi through an ordered probit structure. More speciâ€¦cally,
qi0 = M iÂ¤ hi0 + Â´ i0 < Ãƒ M

(14)

= m iÂ¤ Ãƒ m+1 Â· hi0 + Â´i0 < Ãƒ m , for m = 1; :::M Â¡ 1
= 0 otherwise

q i = M iÂ¤ hi + Â´i < Ãƒ M

(15)

= m iÂ¤ Ãƒ m+1 Â· hi + Â´i < Ãƒ m , for m = 1; :::M Â¡ 1
= 0 otherwise
where

Âµ

Â´ i0
Â´i

Â¶

Âµ Â· 2
Â¸Â¶
Â¾ Â´ Â¾ 0T
Â» N 0;
Â¾ 0T Â¾ 2Â´

(16)

i.e., the unobservables Â´ i0 and Â´ i are distributed joint normal with common variance Â¾ 2Â´ and
with covariance Â¾ 0T .10
Conditional on hi0 , hi , Â¹i , and Â¸i (t), the likelihood function for patient i is given by
Â¹ i (q i jqi0 ; hi ; hi0 ) in (4). In actual computaThis bivariate normal distribution deâ€¦nes Â­i0 (qi0 jhi0 ), and Â­
tion of the likelihood function it is easier to work directly with the joint distribution Â­i (q i ; qi0 jhi ; hi0 ). The
equality of the variance terms is a simpliâ€¦cation.
10

14
the â€œanalyticallyâ€ computable11 equation (4) above. However, hi0 , hi , Â¹i , and Â¸i (t) are
unobserved as they depend on the unobserved characteristic "i . To compute the likelihood,
it is necessary to integrate (4) over the distribution of "i . As there is no analytic solution for
this one-dimensional integral, we simulate it.12 Maximization of the simulated log likelihood
function returns estimates for (Â®; Â¯; Â°; Â±; Ãƒ; Â¾; Â¾ 2Â´ ; Â¾ 0T ) using data (ci ; ti ; qi0 ; qi ; Xi ; Ai ) for a
sample of patients i = 1; :::n.
Several clariâ€¦cations and caveats about the model are in order. First, the four separate
sets of coeÂ¢cients on Xi and Ai (Â®; Â¯; Â°; and Â±) are identiâ€¦ed by the four endogenous
variables. The coeÂ¢cients in hi0 are pinned down by the observed indicators of initial health,
qi0 . Likewise, the coeÂ¢cients in hi are identiâ€¦ed from the observed indicators of â€¦nal health
q i . The coeÂ¢cients in Â¹i and Â¸i (t) are jointly identiâ€¦ed by the completion (ci ) and time in
treatment (ti ) data. Increases in Â¸i (t) decrease the probability of completion. Increases in
Â¹i increase the probability of completion and decrease the expected time until completion
(conditional on completion).13 Second, Xi and Âµi do not enter the ordered probit relationship
between the hâ€™s and the qâ€™s. This is a necessary normalization because coeÂ¢cients on Xi in
the q equations would not be identiâ€¦ed separately from those in the equations for hi0 and
hi . The coeÂ¢cients in hi0 and hi must be interpreted accordingly.14 Third, we suppose that
11

Â­i (q i ; qi0 jhi ; hi0 ) is computed numerically using highly accurate bivariate normal CDFs.
We use an 11-point discretized normal approximation to the distribution of "i .
13
We expect that even more elaborate models can be estimated satisfactorily. For example, consider
allowing Xi and Ai to aÂ¤ect the variance of the Wiener process (Â¾ 2 ). These eÂ¤ects are separately identiâ€¦ed
because a change in Â¾2 has a diÂ¤erent eÂ¤ect on the variance of time until completion than does a change in
Â¹i .
14
As described in more detail later, qi0 and q i are measures of frequency of alcohol consumption (e.g.
once a month, once a week, etc.). Patient characteristics might enter the relationship between h and q if
the relation between health and how much one drinks is diÂ¤erent for diÂ¤erent patients. Importantly, the
potential inclusion of Âµi in the relationship between hi0 and qi0 does not hinder our separate identiâ€¦cation of
population eÂ¤ects and treatment eÂ¤ects. On the other hand, the restriction that Ai does not directly (it can
indirectly enter through Âµ i ) enter this relationship is crucial for this separate identiâ€¦cation of population and
treatment eÂ¤ects. Without this restriction, this implicit normalization would contradict our interpretation
of the agency eÂ¤ect in the equation for hi0 as a pure â€œpopulation eÂ¤ect.â€ We think this is a reasonable
12

15
the health indicator at discharge, q i , is observed only if the patient completes treatment.15
Fourth, we measure time in treatment in weeks, and aggregate the likelihoods accordingly.
Fifth, when we discuss the data in the next section, we will modify our model slightly to
account for patients who are still in treatment at the end of the sample period and to better
account for the empirical time pattern of attrition.
Beside providing a concise and realistic framework for combining information from multiple endogenous outcomes (ci ; ti ; qi0 ; q i ), our structural model solves the endogeneity problem
resulting from a potential correlation between the vector of agency dummies Ai and the unobserved characteristic "i . This solution relies on two key assumptions. First, as discussed
above, the dependent variable qi0 is free of treatment eÂ¤ects. This allows us to estimate
relative population eÂ¤ects from the qi0 equation. Second, unobserved patient characteristics
are summarized by a scalar.16 This allows us to assess the contribution of the population
eÂ¤ects to each dependent variable by conditional covariances of the four variables.17;18
restriction because q is an objective measure of a patientâ€™s condition.
15
We do have some data on health status at discharge for non-completors. We are concerned, however,
about its reliability and are not using it in estimation.
16
While this scalar restriction is signiâ€¦cant, it should capture the â€¦rst order eÂ¤ects of unobserved characteristics and is certainly preferrable to ignoring unobserved characteristics completely.
17
Slightly more formally, we have four dependent variables (ci ; ti ; qi0 ; q i ). There are â€¦ve unobservables in
the model: the Wiener process, the dropout process, the two error terms in the relation between hi0 (hi ) and
qi0 (q i ), and the unobserved patient characteristics. These unobservables are assumed uncorrelated except for
correlation between the two unobservables in the qÂ¡h relationship. Thus, there are three variances (variances
of the unobservable characteristic (") and the dropout process are normalized to 1), one covariance, and three
parameters (Â± 2 ; Â¯ 2 and Â° 2 ) to be identiâ€¦ed by conditional covariances of the four dependent variables. The
eight free elements (two variances must be normalized due to discreteness) in this four by four conditional
covariance matrix appear to be suÂ¢cient to identify these seven parameters. Thus, identiâ€¦cation of the
model (ignoring selection issues - see next footnote), comes from conditional means and variances rather
than higher order distributional assumptions.
18
While the argument in the previous footnote suggests that identiâ€¦cation of our basic model comes from
means and variances and doesnâ€™t rely on precise functional forms for our distributions, there are two data
problems in our particular application that do bring distributional issues into the identiâ€¦cation picture. First,
as is standard in discrete choice models, the discreteness of qi0 and q i requires distributional assumptions
that do aÂ¤ect identiâ€¦cation. An additional issue arises because we only observe q i for completors. This
generates a selection problem. Our model implicitly deals with this selection problem in a Heckman-like
correction. As is usually the case in these selection models, it is likely that the correction does depend on

16
Importantly, this endogeneity issue in our data set would be very hard to deal with in less
structural models. The standard approach would look for instruments that were correlated
with agency assignment yet uncorrelated with unobserved patient characteristics.19 It is
hard to imagine such instruments existing if the endogeneity is due to inherent diÂ¤erences
in patient populations across regions and treatment agencies have diÂ¤erent geographical
footprints.20
There is also a second possible â€œendogeneityâ€ problem arising from the fact that â€œtime
in treatmentâ€ (ti ) and â€œhealth improvementâ€ (4hi ) are determined simultaneously. To
illustrate the problem, consider the hypothetical question: â€œIf a patient were required to
stay in treatment an extra week, what would be the expected increase in the patientâ€™s
health?â€21 One way to answer this question is to estimate a causal â€œproduction functionâ€,
e.g.
4hi = Â¹ti + Â¯Xi + $Ai + & i

(17)

where changes in health are caused by time in treatment. A primary problem in this approach is that the unobservables & i may be correlated with ti . Intuitively, patients that are
the distributional assumptions in the model (e.g. the normality of the unobserved patient characteristics
and the Wiener process).
19
This discussion highlights two general approaches to deal with endogeneity. The â€¦rst and most common
approach is instrumental variables. The second approach, taken here and following Olley and Pakes (1996), is
to use auxiliary equations/data to, in essence, â€œobserveâ€ the unobservables causing the endogeneity problem.
20
More precisely, suppose, for example, that agency assignment is purely regional, e.g. one goes to the
closest agency. Suppose also that there are unobservable diÂ¤erences in patient populations across regions
(our empirical results suggest that this is true). Then there would be literally no possible instruments for
the endogenous agency assignment. Moreover, even if there were other determinants of agency assigment
they may not be feasible instruments. For example, agency budgets may be perceived as good candidates
for instrumenting agency assigment. There are, however, at least two reasons to discard them. First, one
might expect the budget to aÂ¤ect agency decisions on drift and thresholds, in which case they would not be
suÂ¢cient to control for the endogeneity. Second, OSA may have information about the unobservable patient
characteristics and incorporate them in their budget allocation decision, implying correlation between budget
and ".
21
Or perhaps, â€œif we wanted to increase health to a given level, how long would the patient likely have to
stay?â€

17
more easily treated take less time to complete treatment due to unobservable characteristics
that matter for the treatment process. A standard approach to this endogeneity problem
is to identify excluded variables that serve as instruments for ti :22 In contrast to the usual
instrumental variables approach based on exclusion restrictions, our structural model consistently estimates the health production function based on restrictions that arise naturally
from the assumed treatment process. In particular, the assumption that health improvements accrue over time restricts how the variables aÂ¤ecting the drift of the Wiener process
interact with time in treatment.23

2.2

Quantity of treatment

We predict the total cost of treatment for various patient populations in various agencies
with a separate estimation procedure. Given data on agency costs per unit of treatment, a
model of the number of units of treatment provided to a patient is suÂ¢cient to estimate the
cost of treatment. We assume that the units of treatment24 individual i receives, ui , is given
22
The unobservability of 4hi might be dealt with by replacing it with an observable proxy for health
improvement (e.g. reduction in use, q i Â¡ qi0 ) and estimate a probit or logit type model. Lu and McGuire
(2001) employ an approach like this, using the same data set as we do. They use both â€œunits of treatmentâ€
and â€œtime in treatmentâ€ as explanatory variables and agency revenue sources as instruments to control for
the endogeneity of these variables. They do not explicitly address the endogeneity of agency assignment and,
therefore, do not separately identify population from treatment eÂ¤ects.
23
According to our Wiener process model, the production function is:

4hi = Â¹i ti + vi = (Â± 0 Xi + Â± 1 Ai + Â± 2 Âµi )ti + vi
= Â± 0 Xi ti + (Â± 1 + Â± 2 Â®1 )Ai ti + Â± 2 "i ti + vi :
This means that if we could observe 4hi then we would get consistent estimates by dividing through by
t and using OLS, or, alternatively, by using X and A as instruments for Xt and At, respectively. Note,
however, that this simple approach does not separately identify population from treatment eÂ¤ects.
24
In expressing the total units a patient receives in individual therapy units we assume that one unit of
group therapy is equivalent to wg units of individual therapy where wg is the ratio between group therapy
unit costs and individual treatment unit costs. Similarly, one unit of family therapy is equivalent to wf units
of individual therapy where wf is the ratio between family therapy unit costs and individual treatment unit
costs. The left hand side variable is therefore decomposed as follows, where lower case are the actual number

18
by:
ln ui = Â» 0 + Â» 1 Xi + Â» 2 Ai + Â» 3 Âµ i + {i
= Â» 0 + Â» 1 Xi + (Â» 2 + Â» 3 Â®1 )Ai + Â» 3 "i + {i

(18)
(19)

where25 {i is an unobservable term and Â» 2 is a vector of agency treatment eÂ¤ects. {i is naturally correlated with the unobservables governing the treatment process and/or the dropout
process.

For example, patients that drop out prematurely will also tend to receive less

treatment. We can easily obtain the coeÂ¢cients Â» 1 and (Â» 2 + Â» 3 Â®1 ) with an OLS regression,
but this does not separately identify the treatment eÂ¤ect Â» 2 and the population eÂ¤ect Â» 3 Â®1 .
This is unsatisfactory for our purposes. As in the other parts of our model, when we perform the conceptual experiment of moving patients into a diÂ¤erent treatment program, the
population eÂ¤ect should be held constant while the treatment eÂ¤ect should change.
We adopt the following approach to identifying the treatment and population eÂ¤ects for
the units equation. From the estimated treatment model we recover a posterior mean for the
unobservable characteristic "i for each patient i in the sample. This posterior is computed
conditional on the estimated parameters bÌ„; the exogenous data Xi and Ai , and the observed

frequency of use at admission qi0 . Call this posterior pbi . Since by deâ€¦nition
it follows that:

b = pbi
E["i jXi ; Ai ; qi0 ; Â¯]

(20)

"i = pbi + 'i

(21)

of patient units received by patient i as reported in the MATS discharge form:
ln ui = ln(uii + wg Â£ uig + wf Â£ uif ):
25

Again we have redeâ€¦ned the coeÂ¢cients on Xi to include potential correlation between observed and
unobserved characteristics:

19
where 'i is mean independent of Xi ; Ai , and pbi . Substituting this expression for "i into the
units equations yields the estimating equation:

ln ui = Â» 0 + Â» 1 Xi + (Â» 2 + Â» 3 Â®1 )Ai + Â» 3 pbi + Â» 3 'i + {i

(22)

By treating pbi as data, it is possible to estimate (Â» 2 + Â» 3 Â®1 ) and Â» 3 by OLS, and then use the
estimates of Â®1 from section 4 to calculate the treatment eÂ¤ects Â» 2 in the units equation.

In this procedure, it is important to compute the posterior mean for "i by conditioning
only on the initial condition qi0 and not on the endogenous variables (ci ; ti ; qi ). The reason
is that {i likely is correlated with these endogenous variables because of correlation with the
unobservables in the treatment and dropout processes (e.g. random missed appointments
both decrease units of treatment and slow health improvement). There is not a similar
problem with conditioning on qi0 because this variable is determined prior to the treatment
process. Thus, when we only condition on qi0 , it is reasonable to assume that pi is uncorrelated
with {i .
An issue that arises when we estimate the units equation separately from the production
function is that we do not directly estimate covariances between estimated parameters of the
production process and the parameters in the units equation. These covariances are necessary for obtaining standard errors on productivities and the results of our policy analyses
that follow. To obtain these covariances, we bootstrap the estimation routine on resampled
data sets and compute the covariances of the parameters across the bootstraps.26

26

This procedure is less burdensome computationally than the alternative procedure of estimating the
units equation simultaneously with the rest of the model.

20

3

The data

We apply our framework to treatment for alcohol abuse. Our primary data source is the
Maine Addiction and Treatment System (MATS). The data describes people receiving outpatient treatment for alcohol abuse in the State of Maine (U.S.A.) between October 1990 and
June 1996. Maine is mostly rural â€“ in 1994, 35.9% of the population lived in metropolitan
areas compared to 79.8% nationally.27 Parts of the state are particularly remote. Substance
abuse, and especially alcohol abuse, appears to be a serious problem in the state. Almost one
percent of the population receives treatment in state funded substance abuse programs,28
and for 87% of the adults who receive treatment, alcohol is the primary abused substance.29
State government funding for substance abuse treatment was in the neighborhood of $10
million in 1995,30 or about $8 per capita.31
MATS collects data on patients receiving treatment from any publicly funded substance
abuse treatment agency in the state. MATS agencies were required to complete standardized
admission and discharge forms for every treated patient, and to report this data to the
state regulatory agency (OSA).32 Our analysis focuses on the â€¦fteen largest publicly funded
substance abuse agencies, who had a combined budget of $6; 439; 312 in â€¦scal year 1994 of
which $4; 594; 595 was budgeted for outpatient treatment alone.33 Our treatment provider
27

Data are from the census website: http://www.census.gov/statab/www/states/me.txt.
Source: Maineâ€™s application for the Alcohol, Drug Abuse and Mental Health block grants in FY 1992
29
Source: Maine OSA Fact Sheet, â€œAlcohol Use in Maine,â€ 1997.
30
The total budegeted expenditures of the OÂ¢ce of Substance Abuse was $10,085,716. Source: State of
Maine Budget Document, 1994-95.
31
Maineâ€™s population in 1990 was 1.228 million.
32
The Department of Human Services was the relevant agency prior to the creation of OSA. In July
1990, OSA was created as a branch of the Stateâ€™s Executive Department. After July 1, 1996, OSA was
transferred to the Department of Mental Health, Mental Retardation, and Substance Abuse Services (see:
http://www.state.me.us/sos/cec/rcn/apa/depts.htm.) OSA is responsible for allocating state and federal
funds for substance abuse, and for contracting with the agencies receiving these funds.
33
We ignore the agencies that exclusively provide treatment under the Driver Education and Evaluation
28

21
variable Aij is equal to one if patient i is treated at that agency (j = 1; :::15).
Substance abuse patients diÂ¤er with respect to diagnosis and treatment modality. Our
observation unit is a treatment episode, deâ€¦ned by an admission into treatment.34 We focus
on outpatients whose primary diagnosis is alcohol abuse,35 and further restrict the sample to
admissions in the four year period beginning October 1991. We also exclude repeat episodes,
focusing on â€¦rst time clients.
The resulting sample consists of 7601 treatment episodes. Of these, 3402 patients completed treatment, 4040 left treatment prematurely for one reason or another, and 159 were
still in treatment at the end of the sample. To include the on-going patients in our econometric model, we modify the likelihood function in (4) to:
fff (ti ; Â¹i ; Â¾; Â¢hi )[1 Â¡ G(ti ; Â¸i (Â¢))]gci Â£ fg(t; Â¸i (Â¢))[1 Â¡ F (ti ; Â¹i ; Â¾; Â¢hi ]g1Â¡ci
Â¹ i ; hi0 )ci gdi Â£ f[1 Â¡ G(ti ; Â¸i (Â¢))][1 Â¡ F (ti ; Â¹ ; Â¾; Â¢hi ]g1Â¡di(23)
Â¹ i (Â¹
qi jqi0 ; h
Â£Â­i0 (qi0 jhi0 ) Â£ Â­
i
where di = 1 if the patient has been discharged from treatment, and di = 0 if the patient is
still in treatment by the end of the sample. Notice that a patient who completes treatment
(ci = 1) or leaves treatment prematurely (ci = 0) is automatically discharged (di = 1): Table
Program (DEEP). While these agencies treat large numbers of patients, they are intrinsically diÂ¤erent from
regular outpatient treatment. For example, DEEP patients need to complete a certain number of sessions
to recover their licenses. This would entail a very diÂ¤erent model than the one we describe in Section 2.
34
We have also deâ€¦ned as a unique episode all outpatient episodes pertaining to the same patient that
were concurrent in time or less than one month apart. In any of those cases we added the units of treatment
received under each episode and used as admission information the admission information of the â€¦rst episode
and as discharge information the discharge information of the last episode. In most cases the diÂ¤erent episodes
belonged to the same agency but in those cases where the agencies were diÂ¤erent we attributed the merged
episode to the agency where the patient stayed longer.
35
Outpatient treatment is essentially therapy. From the MATS data we distinguish individual, group, and
family therapy as separate modalities. While the MATS data also distinguishes â€œintensive outpatientâ€ and
â€œadolescent outpatientâ€ as distinct modalities, we include these in the category of individual therapy.
The MATS forms distinguish the treatment of primary clients from the treatment of codependents. A
codependent is someone who receives treatment to better deal with someone elseâ€™s substance abuse problem.
We restrict attention to primary alcohol abusers receiving outpatient treatment. A primary patient is
someone receiving treatment for their own substance abuse problem.

22
Average Min Max Std
506.7
101 1388 422.8
Table 2: Statistics on number of patients per agency
Frequency of use at:

completion
abstinent < once daily Â¸ once daily
abstinent (obs=1967)
0.990
0.010
0.000
admission < once daily (obs=1277)
0.856
0.144
0.000
0.968
0.006
0.025
Â¸ once daily (obs=158)
Table 3: Sample transition matrix for completors
1 presents some statistics on number of episodes handled by the â€¦fteen diÂ¤erent treatment
agencies.
Three outcome variables are constructed from the MATS data. First, the discharge form
distinguishes patients who completed treatment from patients who left treatment for other
reasons.36 From this, we deâ€¦ne a dummy variable (ci ) that is equal to one if the patient
completes treatment. Second, from the dates of admission and discharge we construct each
patientâ€™s time in treatment (ti ). Third, the MATS forms report the frequency of alcohol use
at both the time of admission and discharge. We deâ€¦ne two categorical variables (qi0 ; q i ) to
measure frequency of use at admission and completion respectively. These variables equal
zero if the patient has been abstinent for at least one month, one if he currently uses alcohol
less than once a day, and two if his frequency of use is even greater. The sample transition
matrix for frequency of alcohol use is presented in Table 3.
Table 4 presents some summary data on completion of treatment, time in treatment, and
frequency of use at both admission and discharge, in the aggregate population and for the
36

Other reasons for leaving treatment are: 1) client leaves treatment without explanation or refuses treatment; 2) client cannot come to treatment either because of imprisonment or death; 3) and lastly the client
is discharged from treatment due to non-compliance with rules and regulations.

23
Population
mean
s.d.
44:8
49:7
53:2
49:9
2:1
14:3
14:7
16:9
19:0
18:2
11:1
14:7

mean
44:0
52:3
3:7
15:7
20:7
12:3

Agency
min
max
31:7
59:4
22:7
65:6
0:5
18:0
11:7
23:1
13:3
38:0
8:2
20:7

s.d.
9:5
12:2
4:9
3:5
6:7
3:2

abstinent
< once daily
Â¸ once daily

93:9
6:0
0:1

24:0
23:8
3:4

94:8
5:1
0:1

84:1
0:8
0:0

99:2
15:9
1:0

4:4
4:4
0:3

abstinent
< once daily
Â¸ once daily
abstinent
< once daily
Â¸ once daily
abstinent
< once daily
Â¸ once daily

50:2
39:1
10:7
57:8
37:5
4:6
43:9
40:4
15:7
8:6
11:0
6:6

50:0
48:8
30:9
49:4
48:4
21:1
49:6
49:1
36:4
10:4
11:4
9:0

48:3
40:0
11:7
55:8
38:8
5:3
42:1
41:4
16:4
9:5
12:5
7:6

34:7
25:5
6:2
38:2
25:5
1:8
25:0
21:1
10:3
6:2
8:4
4:8

67:8
56:3
20:8
70:7
56:6
11:3
65:8
58:6
23:3
14:9
22:7
11:7

10:7
8:9
4:8
9:6
8:8
3:2
11:9
10:6
4:3
2:5
4:3
2:1

obs=7601
Status at
discharge
Time
in
treatment
Frequency
of use at
completion

Frequency
of use at
admission

% completion (c = 1)
% premature exit (c = 0)
% did not â€¦nish
all
c=1
c=0

c=1

all

c=1

c=0
Units of
treatment

all
c=1
c=0

Table 4: Dependent variables statistics
â€¦fteen agencies. 44.8% of the patients completed treatment successfully (c = 1), and 53.2%
left treatment prematurely while only 2.1% of the patients are still in treatment by the end of
the sample period. However, the patient populations at diÂ¤erent agencies had very diÂ¤erent
average experiences. At the worst agency 31.7% of patients completed treatment, while at
best 59.4% completed treatment. The average agency had 44% completion rate, and the
standard deviation across agencies was 9.5%.
Similar agency heterogeneity is apparent for the average time patients spent in treatment
and for the probability that a patient is abstinent at the time of discharge. The average

24
patient in the sample spent just under 15 weeks in treatment, but this average experience
could vary between just under 12 weeks and just over 23 weeks depending on the agency.
93.9% of patients completing treatment were abstinent at the time of discharge but this
success indicator could be as low as 84.1% or as high as 99.2% depending on the agency.
Our econometric methodology is intended to exploit this heterogeneity in outcomes across
agencies.
It is striking that a high percentage of patients enter treatment reporting that they have
been abstinent over the past month. While a signiâ€¦cant number of the patients come directly
out of the penal system (plausibly explaining their abstinence), it is certainly conceivable
that some patients may be misrepresenting their alcohol consumption prior to admission.
For such â€œmeasurement errorâ€ not to undermine interpretations of empirical results, we
must assume the underreporting does not vary across clinics conditional on observed patient
characteristics X.37
The bar chart in Figure 3 shows attrition for the entire sample population. These are
the number of patients in each week of treatment that left prematurely. Clearly, there is
an extraordinarily high attrition rate in the â€¦rst week. After that, the empirical hazard is
approximately constant. To better account for this pattern we modify our attrition model
to allow for a higher probability of dropping out in the â€¦rst week:
ln Â¸i1 = [Â° 0 Xi + Â° 1 Ai + Â° 2 Âµ i + Â° 3 ]Â° 5 + Â° 4

(24)

The extra coeÂ¢cients Â° 4 and Â° 5 allow the hazard rate to jump discretely after the â€¦rst week.
Other aspects of our model are the same as described earlier.
37

In other words, the underreporting of frequency of use at admission can vary across clinics, but this
either be constant across clinics or be captured by the observables X. Frequency of use at admission is
recorded on the admission form, and in the later part of the sample again on the discharge form. We use the
former. By an oversight the latter was not extracted from MATS, which prevents us from checking reliability.

25
1 0 0 0
9 0 0
8 0 0
7 0 0
6 0 0
5 0 0
4 0 0
3 0 0
2 0 0
1 0 0
0
1

1 2

2 3

3 4

4 5

5 6

6 7

7 8

8 9

1 0 0

1 1 1

1 2 2

1 3 3

1 4 4

Figure 3: Sample attrition
MATS also reports a number of patient characteristics that we include in Xi . Table 5
exhibits summary statistics of these characteristics. 40.2% of patients are male, although
some agencies have predominantly male populations and others the opposite. The average
patient is thirty-something with a monthly household income of about $87138 a month.
Average age is similar across the diÂ¤erent agency populations, but there are clear diÂ¤erences
in the average incomes.
We also include the source of payment for treatment as a patient characteristic. This
could be important for several reasons. The fact that treatment is paid out of pocket,
for example, could inâ€¡uence a patientâ€™s decision to exit treatment prematurely. Source of
payment also impacts reimbursement amounts for agencies, and thus could inâ€¡uence an
agencyâ€™s determination of the completion time and/or the intensity of treatment. 35.1 % of
patients in the sample pay for treatment out of pocket, 17.0% have private insurance, and
another 23.9% are covered by Medicaid or Medicare. Treatment costs for 18.9% of patients in
the sample nominally are covered by public funds allocated to the agency by OSA. Treatment
costs for the small remainder of patients are paid by various other forms of public assistance
and insurance. There is signiâ€¦cant heterogeneity of revenue sources across agencies. It is
38

This is the average monthly income when income is known and stated by the patient and is not bigger
than $9999.

26
also noteworthy that the majority of patients are involved with the legal system in some
way. 21.3% are on parole or probation, and 28.5% are in treatment in connection with
drunk-driving violations.
The last set of patient characteristics are variables relating more directly to a patientâ€™s
health status at admission. First, we construct dummy variables from the clinicianâ€™s assessment of the severity of the patientâ€™s condition, indicating whether the patient is a â€œcasual,â€
â€œlife-style involved,â€ â€œlife-style dependent,â€ or â€œdysfunctionalâ€ user, or if the patientâ€™s severity is â€œundetermined.â€ Second, we construct dummy variables indicating whether in the past
month the patientâ€™s drinking caused problems on the job or at school â€œnot at all,â€ â€œinfrequently,â€ â€œoccasionally,â€ or â€œfrequently.â€ Third, we construct a dummy variable indicating
whether the patient has a concurrent psychiatric condition. All of these dummy variables
are included in our list of patient characteristics (X). The interpretation here is that these
variables are direct predictors of unobserved health status hi0 . In particular, if our observed
severity variable was continuous rather than reported in a coarse ordering, we might expect
it to perfectly measure hi0 (or perhaps a linear combination of severity, problems on the jobs
and psychiatric condition might perfectly measure hi0 ). We also allow the more exogenous
characteristics, i.e. the socioeconomic characteristics, to enter hi0 to the extent that the
discretized variables do not perfectly measure unobserved health. This is important to remember in interpreting the coeÂ¢cients on the socioeconomic characteristics - the coeÂ¢cient
on income, for example, measures the impact of income conditional on our observed severity
measure.
We obtain unit cost data from a separate data set on each agencyâ€™s contracts with OSA.
Each agencyâ€™s annual contract states budgeted total cost and budgeted units of treatment

27

obs=7601
Male
Age
Married
Income (Â·$9999)
Unemployed
Payer

Legal Inv.

Adm. date
Quarter

Severity

Job problems

Pyschiatric problems

OSA
self
private ins.
medicaid/care
other
none
prob./parole
drunk driving
other
days
I
II
III
IV
casual/exp.
involved
dependent
dysfunctional
undetermined
none
infrequent
occasional
frequent

Population
Mean Std.
40.2
49.0
33.1
10.8
23.6
42.4
870.9 885.1
32.2
46.7
18.9
39.2
35.1
47.7
17.0
37.6
23.9
42.6
5.1
21.9
41.3
49.2
21.3
40.9
28.5
45.1
8.9
28.5
11923 394
20.2
40.2
25.4
43.5
27.6
44.7
26.7
44.3
23.4
42.3
17.3
37.8
40.5
49.5
18.4
38.8
0.4
6.4
88.5
31.9
6.3
24.3
2.7
16.3
2.4
15.4
11.7
32.1

Mean
35.6
33.1
24.0
906.8
30.3
17.4
34.5
16.4
24.5
7.2
42.6
21.8
26.4
9.2
11955
20.4
25.8
27.1
26.8
23.8
16.6
42.2
16.8
0.5
86.0
7.3
3.9
2.8
14.4

Table 5: Patient characteristics

Agency
Min
Max
1.6
91.1
30.3
36.2
14.8
28.3
631.4 1172.3
17.4
40.4
0.8
54.3
8.6
61.2
4.7
25.0
15.6
39.5
1.7
18.8
18.2
75.3
9.0
45.1
1.0
49.2
3.8
16.1
11620 12193
10.9
30.7
20.3
31.0
17.8
32.8
20.5
36.7
13.2
44.5
4.5
25.8
29.5
63.4
0.0
43.3
0.0
2.1
60.4
95.8
1.0
14.9
1.2
13.9
0.6
10.9
5.8
41.1

Std
28.8
1.5
3.9
170.7
7.2
15.7
15.3
6.3
6.1
4.5
13.9
10.6
12.6
3.4
152
5.4
3.0
4.2
3.6
10.0
5.7
7.6
12.3
0.7
96.1
4.3
3.5
2.6
10.0

28
for each treatment modality (e.g. group treatment is typically much less expensive than
individual treatment). This gives us unit costs for individual, group and family therapy
for each agency. We use relative unit costs to weight units of group and family therapy
appropriately and construct the variable â€œtotal adjusted units of treatmentâ€ for each patient.
This serves as the dependent variable in the units of treatment equation.39
Total costs for the policy simulations in subsection 4.3 are then constructed by multiplying
predicted â€œadjusted units of treatmentâ€ by the unit cost of individual therapy. In these
simulations we hypothesize that all patients were treated in 1993. 1993 unit costs for each
agency were calculated by deâ€¡ating the nominal unit cost of individual therapy by a 1992
county hospital wage index.40

4

Estimation results

4.1

Population and treatment eÂ¤ects

We focus primarily on our estimates of the treatment eÂ¤ects in the diÂ¤erent agencies. These
measure how the production of health varies between agencies after controlling for both
observed and unobserved characteristics of agency populations. Our estimated coeÂ¢cients
on the Xâ€™s are discussed in the appendix.
Table 6 presents estimated coeÂ¢cients and standard errors for the various population and
39

The calculated weights for group treatment were based on 1990-91 contract data, and for family treatment
1990-94 contract data. It was necessary to â€œcleanâ€ the data with various approximations to deal with the
problems of missing observations, breaks in the series, and other problems.
40
The cost deâ€¡ator is actually a patient-weighted average hospital wage index that accounts appropriately
for multicounty operations of some agencies. We lacked hospital wages for Sagadahoc county, and estimated
the deâ€¡ator for this county by the population-weighted deâ€¡ator of the four neighboring counties.

29
treatment eÂ¤ects.41;42 As discussed earlier, the coeÂ¢cients in the h0 equation are â€œpopulation
eÂ¤ects,â€ measuring how patient populations of the agencies diÂ¤er on average in their unobÂ¹ and Â¸ are the â€œtreatment eÂ¤ects,â€
served characteristics. The coeÂ¢cients reported for Â¹, h,
e.g. for the drift equation, we report Â±1 rather than the total agency eÂ¤ect (Â± 1 + Â±2 Â®1 ). The
reported estimates are expressed as deviations from the population weighted mean, enabling
a clear interpretation of statistically signiâ€¦cant coeÂ¢cients. For example, the fact that the
treatment eÂ¤ect in the drift equation of Agency 1 is positive and signiâ€¦cant indicates that a
patient who remains in treatment at Agency 1 achieves a given completion threshold quicker
than at a randomly assigned agency with the probability of assignment to an agency equal
to the agencyâ€™s population share.
First, the signiâ€¦cance of nine of the â€¦fteen population eÂ¤ects in the â€¦rst column suggests
that these agencies do diÂ¤er in the unobserved characteristics of their populations. As
noted above, this suggests agency assignment is not â€œexogenousâ€ and, given the fact that
most patients attend the nearest clinic, calls into question any potential instruments for
agency assignment. There are also very signiâ€¦cant diÂ¤erences in treatment eÂ¤ects across the
agencies. Eight of the drift eÂ¤ects, twelve of the completion threshold eÂ¤ects, ten of the
dropout probability eÂ¤ects, and eleven of the unit equation eÂ¤ects are signiâ€¦cantly diÂ¤erent
from zero. DiÂ¤erences in the diÂ¤erent dimensions of the treatment process across agencies
do not appear to be independent.

The correlations between the population eÂ¤ect for h0

and the treatment eÂ¤ects for Â¹, h, and Â¸ across the â€¦fteen agencies are reported in Table 7.
Agencies whose patient populations are unobservably healthier at admission do not tend to
41

This table arbitrarily orders agencies. The arbitrary numbering of agencies is necessary to preserve
the conâ€¦dentiality of individual agency information. Hereafter, we identify the individual agencies by this
ranking.
42
Our additive normalization is that
P the average population eÂ¤ect in the hi0 equation is zero (i.e. the
j-dimensional row vector Â®1 satisâ€¦es i Â®1 Ai = 0):

30

h0 (Â®1 )
0
average agency
(0)
Â¡0:3891
agency 1
(0:1470)
0:0035
agency 2
(0:2093)
0:9086
agency 3
(0:1448)
Â¡0:5437
agency 4
(0:1894)
Â¡0:2357
agency 5
(0:2033)
0:2616
agency 6
(0:1100)
Â¡0:1775
agency 7
(0:0582)
Â¡0:0643
agency 8
(0:0937)
Â¡0:8579
agency 9
(0:1908)
Â¡0:8879
agency 10
(0:1693)
0:8383
agency 11
(0:2207)
Â¡0:2578
agency 12
(0:1718)
Â¡0:2549
agency 13
(0:1674)
Â¡0:3125
agency 14
(0:2180)
0:9714
agency 15
(0:1705)

Â¹ (Â± 1 )
Â¡0:0288
(0:0302)
0:0554
(0:0206)
0:0511
(0:0169)
0:0605
(0:0235)
0:0229
(0:0329)
Â¡0:0668
(0:0251)
Â¡0:0036
(0:0106)
0:0037
(0:0089)
Â¡0:0050
(0:0086)
Â¡0:0092
(0:0313)
Â¡0:0231
(0:0280)
Â¡0:0109
(0:0273)
Â¡0:0294
(0:0159)
Â¡0:0331
(0:0138)
Â¡0:0446
(0:0188)
Â¡0:0525
(0:0238)

h (Â¯ 1 )
6:0802
(0:1671)
0:2005
(0:2522)
2:1703
(0:2040)
2:1741
(0:3285)
Â¡0:7319
(0:2176)
Â¡1:4199
(0:2087)
Â¡0:5903
(0:2234)
Â¡0:2458
(0:0673)
0:0341
(0:1973)
Â¡1:3950
(0:2381)
Â¡1:6201
(0:2943)
1:4175
(0:2915)
Â¡1:3045
(0:3076)
0:6574
(0:2931)
Â¡0:3767
(0:3581)
1:3101
(0:3278)

Â¸ (Â° 1 )
Â¡3:9834
(0:1881)
Â¡0:6041
(0:1553)
Â¡0:6601
(0:2427)
0:5162
(0:1781)
Â¡0:4144
(0:2163)
Â¡1:1751
(0:2653)
0:2048
(0:1108)
0:3409
(0:0738)
0:0194
(0:0991)
Â¡0:5406
(0:2463)
Â¡0:8309
(0:2121)
0:4601
(0:2429)
Â¡0:0638
(0:1947)
Â¡0:1275
(0:1674)
Â¡0:1406
(0:2017)
0:2324
(0:2228)

ln(u)
1:6790
(0:1087)
0:2425
(0:0513)
0:6534
(0:1106)
Â¡0:2726
(0:0659)
0:3000
(0:0901)
0:3453
(0:1011)
Â¡0:1731
(0:0403)
Â¡0:2246
(0:0331)
0:0665
(0:0339)
Â¡0:0498
(0:1055)
0:2514
(0:0807)
Â¡0:0565
(0:0993)
Â¡0:0093
(0:0777)
0:2742
(0:0694)
0:2189
(0:0798)
0:0693
(0:0895)

Table 6: Estimated population (h0 ) and treatment eÂ¤ects (in equations for Â¹, h, Â¸) expressed
as deviations from the average agency

31

h0
h0

1

Â¹
h
Â¸

Â¹
0:088
(0:318)
1

h
0:757Â¤
(0:059)
0:476
(0:249)
1

Â¸
0:709Â¤
(0:086)
0:135
(0:281)
0:498Â¤
(0:103)
1

ln(u)

ln(u)
Â¡0:383Â¤
(0:1328)
Â¡0:030
(0:172)
0:017
(0:132)
Â¡0:746Â¤
(0:079)
1

Table 7: Correlation between agency population h0 and treatment eÂ¤ects (Â¹, h, Â¸)
have higher or lower drifts, but do tend to have more demanding completion standards and
more trouble keeping their patients until treatment is complete.
DiÂ¤erences in the population and treatment eÂ¤ects can be summarized by comparing the
proâ€¦le of average patients.

Table 8 presents the averages of the initial health, the drift

of the treatment process, the completion threshold, and the attrition hazard for various
patient populations.43 The requisite health improvement for completion of treatment of the
average patient in the whole sample is Â¢h = h Â¡ h0 = 5:3318: With a drift of Â¹ = 0:1722,
this patient would take almost 31 weeks to complete treatment if there was no attrition.
However, the patient has a 12:7 percent probability of leaving treatment in the â€¦rst week,
and a 3:7 percent probability of premature exit each week thereafter. Thus, the probability
that this patient completes treatment eventually is around 61 percent and the expected
^ 2 = 0:5065: The last column of Table 8 reports the
The estimated variance of the Wiener process is Â¾
average of the time-independent dropout hazard, i.e.:
43

Â¸i (t) = exp(Â° 0 Xi + (Â° 1 + Â° 2 Â®1 )Ai + Â° 2 "i )
The actual time-dependent dropout hazard requires multiplying the reported estimate by eÂ°b 3 t and making
Â° 3 is close to zero, so the
the appropriate adjustment for the â€¦rst period hazard. However the estimated b
reported estimate is very close to the actual hazard after date 1. The date 1 hazard is higher as discussed
earlier.

32
time to completion conditional on not dropping out is 12:2 weeks.44 The big diÂ¤erence in
expected times to completion shows the importance of controlling for the selection problem
in the data. In contrast, the health improvement at completion for the average patient
assigned to Agency 1 is Â¢h = 6:2673. With a more eÂ¤ective treatment regime indicated by
Â¹ = 0:2283, this patient would complete treatment in 27:5 weeks if there was no attrition.
The probability of completing treatment eventually is of 62 percent, and the expected time
to completion conditional on not dropping out is 14:27 weeks. Finally, Table 9 compares
how the average patient in the whole sample fares at each of the agencies. In contrast
to Table 8 these diÂ¤erences are due just to treatment eÂ¤ects. The average patient in the
population completes treatment at Agency 1 after a health improvement of Â¢h = 5:5,
expects to complete treatment after 24 weeks, and has a 73:3 percent probability of successful
completion.

Thus, it appears from these calculations that Agency 1 has a more eÂ¤ective

treatment program than the average agency.
All other estimated coeÂ¢cients are presented and discussed in the Appendix.

4.2

Goodness of â€¦t

How well does the estimated model â€¦t the data? Figures 4 and 5 compare the estimated values and the actual data for time in treatment for diÂ¤erent completion status. The predicted
drop-out hazards tracks the data very closely. The model fares a bit worse at predicting the
timing of the completion of treatment. The estimated model noticeably underpredicts fre44

The probability of completion (conditional on not dropping out) is computed averaging the following
probability across patients:
300 Â³
Â´
X
di )[1 Â¡ G(t; bÌ§i (Â¢))] :
f (t; Â¹
bi ; Â¾
bi ; Â¢h
t=1

33

sample
Agency 1
Agency 2
Agency 3
Agency 4
Agency 5
Agency 6
Agency 7
Agency 8
Agency 9
Agency 10
Agency 11
Agency 12
Agency 13
Agency 14
Agency 15

h0
0:6175
Â¡0:0318
Â¡0:8051
1:7953
Â¡0:1404
Â¡0:3045
0:8029
0:6235
0:3661
Â¡0:4575
0:0208
1:9920
0:3885
0:5707
0:1452
1:6040

Â¹
0:1722
0:2283
0:1279
0:2027
0:1821
0:1366
0:1876
0:1922
0:1669
0:1750
0:1260
0:1801
0:1544
0:1131
0:1380
0:1126

h
5:9493
6:2355
6:8785
7:6499
5:4164
4:4338
4:9980
6:0712
5:8530
5:0079
5:6259
7:0329
4:7925
7:0552
5:7866
6:2267

Â¸ eÂ¡Â° 3 t
0:0368
0:0318
0:0281
0:0286
0:0457
0:0091
0:0328
0:0583
0:0409
0:0531
0:0425
0:0185
0:0420
0:0402
0:0444
0:0146

Table 8: Estimated treatment process for average patients

Agency 1
Agency 2
Agency 3
Agency 4
Agency 5
Agency 6
Agency 7
Agency 8
Agency 9
Agency 10
Agency 11
Agency 12
Agency 13
Agency 14
Agency 15

h0
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175
0:6175

Â¹
0:2275
0:2233
0:2327
0:1951
0:1054
0:1685
0:1758
0:1672
0:1630
0:1491
0:1613
0:1428
0:1391
0:1276
0:1196

h
6:1498
8:1196
8:1234
5:2174
4:5294
5:3591
5:7036
5:9835
4:5543
4:3292
7:3669
4:6448
6:6068
5:5726
7:2594

Â¸eÂ¡Â° 3 t
0:0201
0:0190
0:0616
0:0243
0:0114
0:0451
0:0517
0:0375
0:0214
0:0160
0:0583
0:0345
0:0324
0:0320
0:0464

Table 9: Estimated average treatment process for the whole sample when treated at diÂ¤erent
clinics

34

0 .1 4
0 .1 2

P ro b

0 .1
0 .0 8
0 .0 6
0 .0 4
0 .0 2

97

89

81

73

65

57

49

41

33

25

17

9

1

0

W eek
D a ta

Model

Figure 4: Probability of droping out in date t
quency of completions in weeks 12-15, and slightly overpredicts completions in weeks 21-27.
Still, the â€¦ts seem reasonable given the parsimony of our model of the treatment process.
We have also estimated the frequency of use of all patients conditional on the probability
of completion. A comparison of Tables 3 and 10 shows that the model predicts quite well the
frequency of use at completion of patients who are light alcohol users at admission, while it
underpredicts the probability of abstinence at completion of heavier drinkers at admission.

4.3

Productivity comparisons

We next compare the productivities of these â€¦fteen treatment agencies. Our estimated model
enables us to compute the hypothetical aggregate health improvement and total costs for any

35

0 .0 3
0 .0 2 5

P ro b

0 .0 2
0 .0 1 5
0 .0 1
0 .0 0 5

97

89

81

73

65

57

49

41

33

25

17

9

1

0

W eek
D a ta

Model

Figure 5: Probability of Completing in date t
population of patients assigned to any treatment program.

We consider sixteen possible

patient populations â€“ the sample populations of each of the â€¦fteen treatment agencies as
well as the entire sample population, and can match these sixteen patient populations to the
â€¦fteen agencies in all possible ways. To better visualize these conceptual experiments consider
the problem of comparing the productivity of two diÂ¤erent teachers in a school. A simple
and natural experiment for comparing teaching productivities would be to switch teachers,
Frequency of use at:

Expected frequency of use at completion
abstinent < once daily Â¸ once daily
abstinent
0:9864
0:0135
0:00015
admission < once daily
0:9236
0:0742
0:00223
0:7564
0:2252
0:01844
Â¸ once daily

Total
1:0
1:0
1:0

Table 10: Average estimated frequency of use across all patients conditional on the probability of completion

36
keeping classes â€¦xed, and measure the performance of each class under each teacher. This
type of comparison implicitly controls for diÂ¤erent characteristics of the two classes. Our
simulations emulate similar controlled experiments in a health services treatment setting.
Productivity is a standard measure of economic eÂ¢ciency. In manufacturing industries,
productivity is measured simply by dividing aggregate output by aggregate cost. In a health
services setting, however, the measurement of productivity is complicated by the fact that it
is not clear how to most appropriately measure output. The most obvious output measure
in our setting is health improvement, i.e. the change in the latent variable representing
the health of the patient.

Thus, output is Â¢hi = hi Â¡ h0i for a patient who completes

treatment (since by deâ€¦nition, patients who have completed treatment have achieved level
hi ). For patients who drop out prematurely, output is hti Â¡ h0i , where t is the time of
dropout. Aggregate output is measured by summing expected health improvement over the
patient population being considered. Aggregate cost is measured by multiplying an agencyâ€™s
estimated total units of treatment by its unit cost of treatment. These measures enable our
productivity calculations.45
More precisely, consider the expected total increase in latent health that would result
if agency k were to treat population j. The fact that we have separated population and
treatment eÂ¤ects is critical for this procedure. When agency k treats population j, we use
the treatment eÂ¤ects of agency k, but the population eÂ¤ects of population j. In other words,
the fact that population j is relatively hard or easy to treat goes with that population when
we move the population to diÂ¤erent agencies. The fact that agency k is more or less eÂ¤ective

45

The Appendix considers aggregate abstinence as an alternative output measure. In the the next section,
we consider some conceptual problems with using these productivity estimates to measure economic eÂ¢ciency,
and adopt a less restrictive approach.

37
(Â± 1 ), or has diÂ¤erent completion thresholds (Â¯ 1 ), etc. stays with the agency as we assign to it
diÂ¤erent patient populations. In some cases, we compare our results and policy predictions
to simulations in which we naively assume that all the patient populations are unobservably
identical, i.e. where there are no population eÂ¤ects.
b ; bÌ§ ; Â¾
Given our estimated parameters (b
hi0 ; Â¹
bik ; h
ik
ik ^ ; i = 1; :::N ); the total expected in-

crease in health of population j at agency k is given by the following formula:
N
X
i=1

1
Â³
Â´
X
b
b
Aij E"i [(hik Â¡ hi0 )
f (t; Â¹
hik Â¡ b
hi0 ) 1 Â¡ G(t; bÌ§ik ) dt +
bik ; Â¾
b; b

0

t=1

1
X
B
b
b
BÂ¹
@bik t Â¡ 2(hik Â¡ hi0 ) exp
t=1

Ãƒ

2b
Â¹ik (b
hik Â¡ b
hi0 )
2
Â¾
b

b Â¡b
hi0 )dt]
Â£g(t; bÌ§ik )(1 Â¡ F (t; Â¹
bi ; Â¾
b; h
ik

!

Â©

Âµ

Â¡(b
hik Â¡b
Â¹ik t
hi0 )Â¡b
p
Â¾
b t

Â¶

1 Â¡ F (t; Â¹
hik Â¡ b
hi0 )
bi ; Â¾
b; b

1
C
C
A

(25)

The â€¦rst line of the expression gives the expected health improvement conditional on completion multiplied by the probability of completion. The next two lines give the expected health
improvement conditional on premature exit at each date t, multiplied by the probability of
exit at that date, and summed over all possible exit dates.46 To actually compute (25), we
simulate the expectation over the distribution of the unobserved characteristics "i .47
We divide this measure of aggregate output by aggregate cost to calculate productivity.
Aggregate cost is measured by multiplying the predicted treatment units for patient i in
agency k; from equation (22), by the unit cost of agency k. As explained earlier, we translate
all units of treatment into equivalent units of individual therapy, and use the unit cost of
46

The formula for expected health improvement conditional on not having completed at date t can be
found in Lancaster (1990, pp. 119-121).
47
The simulation truncates the inâ€¦nite sum of completion dates at T = 300. As the probability of a patient
staying more than even 200 weeks is extremely small, there is no apparent diÂ¤erences between truncating
the sum at 200 or 300.

38
individual therapy for â€¦scal year 1993. In doing so, we are implicitly assuming that unit
costs are exogenously â€¦xed and do not vary with the patient population. The reason for
choosing â€¦scal year 1993 for these productivity comparisons is that all agencies had programs
running in that year and therefore we have comparable cost information.
The estimated productivities for agencies treating their own patient population and the
entire sample population are presented in Table 11. There are three columns in the table.48;49
The â€¦rst reports the productivities of each agency when treating its own population. These
productivities do not control for diÂ¤erences in either observed or unobserved patient characteristics across agencies. The second column simulates productivities for each agency
treating the entire sample population under the naive assumption that there are no population eÂ¤ects, i.e. that the estimated agency â€¦xed eÂ¤ects in the drift, threshold, dropout,
and units equations are entirely treatment eÂ¤ects. This comparison controls for observable
patient characteristics (because all agencies are treating the same population) but makes no
attempt to control for population diÂ¤erences in the unobservable characteristic. The last
column reports simulated productivities of the entire population that account appropriately
for the estimated population eÂ¤ects. This last simulation accounts for both observable and
unobservable diÂ¤erences across patient populations.
48

In making these calculation we assume that all patients enter treatment beginning in January 1993. We
adjust the time dependent variables in our estimated treatment model accordingly, and use unit cost data
for this year. The numbers presented in Tables 11, 17, and 18 (see appendix) have been multiplied by 1000.
49
As the estimated productivities are highly non-linear functions of the parameters, we compute their
standard errors by bootstrapping the data and estimation. Since actual estimation is very time consuming
(1 to 2 weeks of CPU time), we follow Andrews(1999) suggestion and use a K-step bootstrap. Using the
actual estimates as starting parameters, we take K Gauss-Newton steps with the resampled data. While
Andrews suggests that K = 10 or 20 works reasonably in many cases, we use K = 100, which still leads to
a signiâ€¦cant time savings.
The same bootstrapping methodology is used in our technology transfer experiment below. This is
necessary because we employ separate estimation procedures for the basic model and one for the units
equation. The bootstrap simulations provide conâ€¦dence intervals that account for the correlations between
the estimated parameters in the two sets of equations.

39
Table 11 reveals signiâ€¦cant diÂ¤erences of the productivities of the agencies. Agency productivities are as high as 12.87 and as low as 5.62, a diÂ¤erence of two to three times the
â€œhealthâ€ per dollar spent. There are also notable diÂ¤erences in the ranking of agencies across
the columns. Ignoring both observable and unobservable diÂ¤erences in the agency populations leads to the conclusion that Agency 1 is the top performer and Agency 13 the worst. In
contrast, recognizing and controlling only for observable population diÂ¤erences shows that
Agency 2 is the best performer and Agency 15 the worst, while controlling for all diÂ¤erences
in population, Agency 2 remains the best and Agency 10 is the worst.
The diÂ¤erence between the estimated productivites in â€¦rst and second columns of Table
11 can be interpreted as capturing the eÂ¤ect of controlling for the observable characteristics.
Analogously, the diÂ¤erence between the second and third columns captures the eÂ¤ect of
controlling for unobservable characteristics. The variance of the â€¦rst eÂ¤ect (the diÂ¤erence
between columns 1 and 2) across agencies is 1.52 while the variance of the second eÂ¤ect (the
diÂ¤erence between columns 2 and 3) is 2.00. This suggests that controlling for diÂ¤erences in
unobserved characteristics across agencies is as much, if not more, important than controlling
for observed characteristics.

4.4

EÂ¢ciency frontiers

While productivities often are convenient and intuitive measures of economic eÂ¢ciency, productivity comparisons can tell a misleading story in a health services setting. While manufacturing industries do not produce outputs without inputs, it is not necessarily true that
patients would not recover without health treatment. Unfortunately, our data set does not
contain any observations on patients not entering treatment, which prevents us from directly

40

Own population
Agency

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

product.

12:87
(0:895)
12:08
(1:480)
8:38
(0:591)
9:45
(1:517)
10:94
(1:450)
9:10
(0:654)
9:34
(0:587)
7:90
(0:528)
8:83
(1:144)
7:12
(0:733)
10:30
(1:245)
9:96
(0:937)
5:62
(0:814)
8:87
(1:228)
6:69
(0:782)

ranking

1
2
11
6
3
8
7
12
10
13
4
5
15
9
14

Entire population
NOT accounting for pop. eÂ¤.
product.
ranking

Entire population
accounting for pop. eÂ¤.
product.
ranking

12:88
(0:940)
15:50
(1:477)
8:11
(0:620)
10:48
(1:359)
10:01
(1:619)
8:37
(0:702)
8:86
(0:645)
8:04
(0:553)
8:97
(1:109)
8:55
(0:719)
8:74
(1:216)
9:58
(0:930)
7:26
(0:758)
8:70
(1:208)
6:31
(0:803)

10:96
(0:842)
14:95
(1:347)
9:33
(0:902)
8:36
(1:045)
8:45
(1:219)
8:71
(0:894)
8:09
(0:542)
7:55
(0:542)
6:27
(0:846)
5:67
(0:750)
10:17
(1:560)
8:17
(0:938)
6:61
(0:685)
7:59
(1:048)
7:87
(1:319)

2
1
13
3
4
11
7
14
6
10
8
5
12
9
15

2
1
4
7
6
5
9
12
14
15
3
8
13
11
10

Table 11: Agency rankings according to estimated productivities in terms of health

41
addressing this issue.50
Using the productivity measures as comparative eÂ¢ciency indicators implicitly assumes
that patients would not change health status if they were not to receive treatment. Figure
6, which graphs total costs vs. total health improvement, illustrates the problem. Given
a particular patient population, we can plot diÂ¤erent agencies on this graph according to
their total costs of treating this population and the total health improvement achieved.
Productivities equal the slope of the line between each agency point and the origin. Thus in
Figure 6 Agency A has the highest productivity and Agency C the lowest. Suppose, however,
that instead of getting 0 health improvement with no treatment, untreated patients were to
achieve a total health improvement of 10. In this case, the â€œtrueâ€ productivity of treatment
would equal the slope of the line connecting each agency point to the point 10 on the vertical
axis, and the ranking of productivities would be exactly reversed.
Another possible problem with a productivity measure based on the ratio of total output
per total cost is the possibility of diminishing or increasing returns to treatment at the level
of the individual patient. Suppose some agencies tend to give each patient more intense
treatment than other agencies (e.g. more units of treatment per week), one might expect to
â€¦nd diminishing returns, i.e. patients marginal health improvement from an extra dollar of
treatment declines as the intensity of treatment increases. As can be easily observed from
the example in â€¦gure 6, the productivity measures are simply the magnitude of the slopes
of straight lines joining each point A, B, and C with the origin, and, therefore, in the case
where the true production function is concave we may wrongly conclude that agency C is
performing badly when in fact agency C is on the production frontier.51
50
51

See the Appendix for some observations in reference to the received substance abuse treatment literature.
Note that our model implicitly does not allow increasing or decreasing returns to the amount of time a

42

20
C

Tota l He a lth Im prove m e nt

18
B

16
14
A

12
10
8
6
4
2
0
0

5

10

15

20

25

30

35

To ta l Co st of Tre a tm e n t

Figure 6: An example of health improvement versus total costs

There are several possible avenues of attack on these problems. One possibility is to use
our structural model to â€œscale upâ€ or â€œscale downâ€ production at the various agencies to
bring them to comparable points. For example, we could scale up production at Agency A
and scale down production at Agency C so that all three agencies produce the same level of
health. One could then compare costs to rank the diÂ¤erent agencies. While this is possible
in our model, it is not clear on what margins to scale production. For example, for Agency
C we could either decrease its completion standards or decrease the amount of treatment it
is giving patients per week. Another issue is that in doing this, we would need to presume
that the other treatment eÂ¤ects for the agency remain the same. It might be inappropriate,
for example, to assume that increasing the amount of treatment per week doesnâ€™t aÂ¤ect
patient spends in treatment or scale economies in the number of patients receiving treatment.

43
dropout probabilities.

A second solution would be to postulate social preferences over

health/cost space, e.g. draw indiÂ¤erence curves in Figure 6 and rank agencies based on these
indiÂ¤erence curves. However, we have no particular insight into how society values latent
health improvements.
We adopt what seems like a less presumptuous approach by limiting ourselves to conclusions about the relative performance of agencies that have a dominance relationship. That
is, if a certain agency provides a given population with no more health improvement than
would another agency and yet has higher total costs, then we conclude that the â€¦rst agency
is dominated and not performing eÂ¢ciently.

On the one hand, this relative performance

comparison makes no assumptions about either the eÂ¤ects of no treatment, economies of
scale in treatment intensity, or societal preferences, other than that the same amount of
treatment for lower cost is better.

On the other hand, this is admittedly a conservative

approach to comparing the performances of the treatment agencies, because it implicitly
only values cost reductions and not health improvements.
Figure 7 plots our â€¦fteen agencies in health/cost space. These points examine the situation in which each agency treats the entire population, controlling appropriately for population and treatment eÂ¤ects. An agency is dominated in this experiment if there is another
agency to the northeast of it on the diagram. As can be seen, there are a number of dominated agencies. For example, Agencies 9 and 10 provide less health than Agency 11, but
spend almost double the money on treatment; Agency 13 provides less health than Agency
4, but spends $500,000 more. The only agencies that are not dominated are Agencies 2, 4,
6, 11, and 12.

One can visualize a downward sloping eÂ¢ciency frontier on the diagram,

specifying for any given total cost the total health improvement that an eÂ¢cient agency can

44

40000

2

Total Health Improvement

35000

30000

1
25000
3

20000

8

5
15000

6

13

4

11

7

15

9

10

14

12
10000
1000000

1500000

2000000

2500000

3000000

3500000

Total Costs of Treatment

Figure 7: Health improvement versus costs

produce. We can conclude that the dominated agencies are not on this frontier, i.e. would
not provide treatment to the entire population eÂ¢ciently. While we cannot necessarily conclude that the undominated â€¦rms are on the true frontier (i.e. the frontier may lie to the
northeast), we will loosely describe them as â€¦rms on the eÂ¢ciency frontier.
These eÂ¢ciency â€¦gures are just point estimates. Using our resampling bootstrap methods
(see footnote 46), we can statistically test whether â€¦rms are ineÂ¢cient. For a given number
of bootstrapped parameter vectors, we compute how many times a particular agency is
undominated, i.e. when the agency is on the eÂ¢ciency frontier. The proportion of bootstrap
repetitions when this occurs serves as a p-value for the null hypotheses that a â€¦rm is on the
frontier. For example, if an agency is on the frontier in only 3% of the bootstrap repetitions,
we reject the null hypothesis that the agency is eÂ¢cient with 97% conâ€¦dence. We can reject

45
that Agencies 8, 9, 10, and 13 are eÂ¢cient with at least 95% conâ€¦dence. Agency 2 is the
only â€¦rm that we can reject being dominated by another â€¦rm.52

4.5

Transfering of best practices

The above analysis considers the health/cost trade-oÂ¤ for the entire patient population. We
also examine these trade-oÂ¤s for each particular agencyâ€™s patient populations by constructing
similar â€¦gures. For each agencyâ€™s population we compare the estimated outcomes and costs
of treatment against the simulated outcomes and costs if the population were treated by
other agencies. In particular, we note whether there is another agency that can provide at
least the same amount of health as the originating agency, but at lower cost. If there are
multiple agencies that can provide more treatment at less cost, we choose the lowest cost
agency. The â€¦nal goal of this exercise is to estimate a lower bound of how much money Maine
could save (without compromising health outcomes) by transferring the practice styles of the
more eÂ¢cient agencies.
Table 12 reports estimated savings that could be achieved by â€œtransferring best practicesâ€
of more eÂ¢cient agencies. We order the results by the total cost savings, i.e. transfers that
save the most money are listed â€¦rst. The â€¦rst transfer has Agency 10 transferring its practice
style to Agency 5, saving $46,000, more than 2% of the overall expenditures (at all â€¦fteen
clinics). There are a total of ten cost-saving transfers - there is no potential cost savings
for Agencies 2, 4, 6, 11, and 12. The total cost saving due to the ten transfers is $163,000,
7.4% of the total budget for the â€¦fteen agencies. Bootstrapped standard errors show that
52

More details on these tests are in the Appendix in comparison to similar tests using abstinence as an
output measure.

46
transferring practice styles between clinics can lead to signiâ€¦cant cost savings.53;54
The virtue of using our measure of latent health as an output measure is that it eÂ¤ectively
combines information from multiple output measures. However, one can also use single, yet
more tangible, output measures. Table 1 in the introduction reproduces the analysis using
abstinence. Other output measures such as, for instance, completion of treatment could
be used as well. Comparing tables 1 and 12, the agencies that would most beneâ€¦t from
technology transfer are similar, but the agencies who transfer the practices are somewhat
diÂ¤erent. As noted above, we favor the â€œlatent healthâ€ results since they use information
from all the output measures in our dataset.

4.6

Explaining superior performance

In this section we present some evidence that supports the idea that the superior performance of certain agencies is idiosyncratic, i.e. due to diÂ¤erences in practice styles, and not
related to observable and exogenous agency characteristics. We concentrate on two agency
characteristics: size, and importance of group treatment vis-a-vis individual therapy. Size
is measured by the average annual budget for (individual, group and family) outpatient
treatment,55 and group units is the ratio between adjusted units of group treatment and
total units of treatment.56 We normalized size by dividing it by its standard deviation.
53

Importantly, with our bootstrapped parameter vectors, we do not recompute the optimal transfers. As
such, some of these transfers can potentially cost money (for particular bootstrapped parameter vectors).
54
Note that while the direct eÂ¤ect of these transfers is to save money, there are also a potential side eÂ¤ect
of improving health outcomes (since in some cases the new â€œownersâ€ not only save money but produce more
health). For both outcome variables, health improvement (abstinence rates) goes up a total of about 1-2%
with the transfers.
55
We ignore the budget for evaluation because we have excluded from our sample patients who only
received evaluation.
56
We use the same approach as in Section 2.2. In order to obtain a total number of units we add family
and group units after we multiply them by their weights. Again their weights are given by their relative costs
in terms of â€œindividualâ€ treatment. Lastly evaluation units are assumed to be equivalent to â€œindividualâ€

47

Controlling for Unobservable Population EÂ¤ects
Population of Treated by
Cumulative
Agency
Agency
$ Savings $ Savings
46131:43
10
5
46131:43
(14573:13)
77079:50
13
4
30948:07
(22078:73)
95844:76
15
11
18765:26
(24922:34)
113109:82
7
11
17265:06
(44368:38)
130003:33
3
2
16893:51
(52250:61)
139445:31
14
11
9441:98
(55455:86)
148404:26
8
4
8958:95
(72829:64)
157080:89
9
5
8676:63
(73558:75)
160334:31
5
11
3253:42
(74488:06)
162551:37
1
2
2217:06
(81150:72)
162551:37
11
11
0
(81150:72)
162551:37
6
6
0
(81150:72)
162551:37
4
4
0
(81150:72)
162551:37
12
12
0
(81150:72)
162551:37
2
2
0
(81150:72)

Cumulative
% Savings
0:0210
(0:0067)
0:0351
(0:0100)
0:0436
(0:0114)
0:0515
(0:0202)
0:0592
(0:0237)
0:0635
(0:0252)
0:0675
(0:0331)
0:0715
(0:0335)
0:0730
(0:0339)
0:0740
(0:0369)
0:0740
(0:0369)
0:0740
(0:0369)
0:0740
(0:0369)
0:0740
(0:0369)
0:0740
(0:0369)

Table 12: Cost reducing technology transfers, controlling for population eÂ¤ects in terms of
health

48
agency category
size
% group

good
mean
0:037
1:136

s.d.
0:032
0:555

medium
mean s.d.
0:066 0:063
1:663 1:261

poor
mean
0:067
1:291

s.d.
0:055
1:261

Table 13: Mean and variances of agency characteristics by agency category
The correlation between these two agency characteristics is around 0:35. In order to show
approximately how these agency characteristics correlate with performance, we categorize
agencies into three groups according to their proximity to the eÂ¢ciency frontier (see â€¦gure 7).57 Table 13 shows the mean and variance for the variables across the three agency
categories.58

These results suggest that superior performance is likely to reâ€¡ect diÂ¤erent

â€œpractice styles.â€

5

Conclusions

We have developed and applied a methodology for comparing the performance of providers of
alcohol abuse treatment in Maine. Our results should be interpreted tentatively for drawing
speciâ€¦c policy conclusions about alcohol abuse treatment in Maine. It is certainly possible
to analyze more data more extensively. Nevertheless, our analysis of the Maine data illustrates a sound methodology for relative performance evaluations that is potentially a useful
public policy tool. The methodology enables a separate identiâ€¦cation of agency â€œpopulatreatment units.
57
Good performers include agencies f2; 4; 6; 11; 12g, bad performers include agencies f8; 9; 10; 13g and
medium performers include agencies f1; 3; 5; 7; 14; 15g.
58
We made simple tests on the equality of means across agency categories. We were not able to reject that
the mean of â€œpercentage groupâ€ of good performers is lower than the mean for medium and bad performers.
For the variable size we were never able to reject the null of common means across agency categories. All
tests were done assuming the variables were normally distributed. Finally we ran simple OLS regressions
with the classiâ€¦cation into the three groups as the dependent variable and size and percentage group as
explanatory variables. Conditioning on percentage group made the size coeÂ¢cient positive although small
and not statistically diÂ¤erent from zero. The group coeÂ¢cient was negative but not statistically signiâ€¦cantly
diÂ¤erent from zero.

49
tion eÂ¤ectsâ€ and â€œtreatment eÂ¤ectsâ€ which enables us to compare how diÂ¤erent agencies
would perform treating the same populations.

We conclude that diÂ¤erent agencies have

signiâ€¦cantly diÂ¤erent treatment eÂ¤ects, governing the eÂ¤ectiveness of treatment, standards
of completion of treatment, and the ability to retain patients until they complete treatment.
To the extent that these diÂ¤erences reâ€¡ect diÂ¤erences in practice style or management techniques, we conclude that Maine potentially could improve the cost eÂ¤ectiveness of publicly
funded treatment substantially by identifying and transferring best practices.59

References
[1] Aitken, L.S. (1986), â€œRetrospective Self-Reports by Clinets DiÂ¤er from Ongoing Reports: implications for the evaluation of drug treatment programs,â€ International Journal of Addictions, 21(7), 767-788.
[2] Andrews, Donald W. K.(1999), â€œHigher-order Improvements of a Computationally Attractive k-step Bootstrap for Extremum Estimators,â€ Cowles Foundation Discussion
Paper, No 1230.
[3] Anglin, M. D. and Y. Hser (1990), â€œTreatment of Drug Abuse,â€ in: Tonry, M. and J.Q.
Wilson (Eds), Crime and Justice: an annual review of research, vol 13. University of
chicago Press.
[4] Apsler, Robert and Wayne Harding (1991), â€œCost-EÂ¤ectiveness Analysis of Drug Abuse
Treatment: current status and recommendations for future research,â€ in: Drug Abuse
Services Research Series, No 1: Background Papers on Drug Abuse Financing and Ser59

There is a large literature on the eÂ¤ectiveness of substance abuse treatment. The Appendix contains a
brief discussion of how our approach and results relate to that literature.

50
vices Research. National Institute on Drug Abuse. DHHS Pub. No. (ADM) 91-17777.
Washington, D.C., 58-81.
[5] Apsler, Robert (1991), â€œEvaluating the Cost-EÂ¤ectiveness of Drug Abuse Treatment
Services,â€ in: Economic Costs, Cost-EÂ¤ectiveness, Financing and Community-Based
Drug Treatment. Rockville, MD: National Institute on Drug Abuse, Research Monograph Series 113, 17-26.
[6] Ball, John C. and Alan Ross (1991), â€œThe EÂ¤ectiveness of Methadone Maintenance
Treatment: patients, programs, services, and outcome.â€ Springer-Verlag New York Inc.
[7] Bound, John (1991),â€œSelf-Reported vs Objective measures of Health in retirement models,â€ Journal of Human Resources, 26, 107-137.
[8] Butler, J. S., Richard V. Burkhauser, Jean Mitchell and Theodore P. Pincus (1987),
â€œMeasurement Error in Self-Reported Health Variables,â€ The Review of Economics and
Statistics, 69, 644-650.
[9] Commons, Margaret, Thomas G. McGuire, and Michael H. Riordan (1997), â€œPerformance Contracting for Substance Abuse Treatment,â€ Health Sciences Research, 32 (5),
631-650.
[10] Commons, Margaret and Thomas G. McGuire (1997), â€œSome Economics of Performance
Based Contracting for Substance Abuse Services,â€ in: Egertson, Joel A, Daniel M. Fox,
and Alan I. Leshner (Eds), Treating Drug abusers EÂ¤ectively. Milbank Memorial Fund
and Blackwell Publishers, 223-249.
[11] Drummond, D. Colin (1997), â€œWhat I Would Most Like to Know. Alcohol Interventions:
do the best things come in small packages?,â€ Addiction, 92(4), 375-379.

51
[12] Eckstein, Zvi and Kenneth Wolpin (1999), â€œWhy Youths Dropout of High School: the
impact of preferences, opportunities and abilities,â€ Econometrica, 67(6), 1295-1339.
[13] Emrick, Chad D. (1975), â€œA Review of Psychological Oriented Treatment for Alcoholism
II - the relative eÂ¤ectiveness of diÂ¤erent treatment approaches and the eÂ¤ectiveness of
treatment versus non-treatment,â€ Journal of Studies on Alcohol, 36, No 1, 88-108.
[14] Finney, John W., Annette C. Hahn and Rudolf H. Moos (1996), â€œThe EÂ¤ectiveness of
Inpatient and Outpatient Treatment for Alcohol Abuse: the need to focus on mediators
and moderators of setting eÂ¤ects,â€ Addiction, 91(12), 1773-1796
[15] French, Michael T., Gary A. Zarkin, Robert L. Hubbard, and J. Valley Rachal (1991),
â€œThe Impact of Time in Treatment on the Employment and Earnings of Drug Abusers,â€
American Journal of Public Health, 81(7), 904-907.
[16] Gerstein, D. R. and H. J. Hardwood, (Eds) (1990), Treating Drug Problems. Washington, D.C.: Institute of Medicine, National Academy Press.
[17] Grant, Kathryn A., Lisa T. Arciniega, J. Scott Tonigan, William R. Miller and Robert
Meyers (1997), â€œAre Reconstructed Self-Reports of Drinking Reliable?,â€ Addiction,
92(5), 601-606.
[18] Heckman, J. J. (1997), â€œInstrumental Variables: a Study of Implicit Behavioral Assumptions Used in Making Program Evaluationsâ€, Journal of Human Resources, 32,
442-461.
[19] Heckman, J. J. and JeÂ¤rey A. Smith (1995), â€œAssessing the Case for Social Experiments,â€ Journal of Economic Perspectives, 9(2), 85-110.

52
[20] Higgins, Stephen T., Alan J. Budney, Warren K. Bickel, and Gary J. Badger (1994),
â€œParticipation of Signiâ€¦cant Others in Outpatient Behavioral Treatment Predicts
Greater Cocaine Abstinence,â€ American Journal of Drug and Alcohol Abuse, 20(1),
47-56.

[21] HÃ¸yer, Georg, Odd Nilssen, Tormod Brenn, and Helge Schirmer (1995), â€œThe Svalbard
Study 1988-89: a unique setting for validation of self-reported alcohol consumption,â€
Addiction, 90, 539-544.

[22] Imbens, Guido W. and Joshua D. Angrist (1994), â€œIdentiâ€¦cation and Estimation of
Local Average Treatment EÂ¤ects,â€ Econometrica, 62 (2), 467-475.

[23] JaÂ¤e, Jerome, H. (1984), â€œEvaluating Drug Abuse Treatment: a comment on the state
of the art,â€ in: Tims, F. M. and J.P. Ludford (Eds), Drug Abuse Treatment Evaluation: Strategies, Progress and Prospects. National Institute on Drug abuse Research
Monograph No. 51. Rockville, MD, 13-28.

[24] Joe, George W., D. Dwayne Simpson and S.B. Sells (1994), â€œTreatment Process and
Relapse to Opiod Use during Methadone Maintenance,â€ American Journal of Drug and
Alcohol Abuse, 20(2), 173-197.

[25] Keane, Michael and Kenneth Wolpin (1997), â€œThe Career Decisions of Young Men,â€
Journal of Political Economy, 105, 3rd issue, 473-522.

[26] Lancaster, Tony (1990), The Econometric Analysis of Transition Data, Econometric
Society Monographs No 17..Cambridge University Press.

53
[27] Long, Clive G., Martin Williams, and Clive R. Hollin (1998), â€œTreating Alcohol Problems: a study of programme eÂ¤ectiveness and cost-eÂ¤ectiveness according to length and
delivery of treatment,â€ Addiction, 93(4) 561-571.
[28] Longabaugh, Richard, Philip W. Wirtz, Allen Zweben, and Robert L. Stout (1998),
â€œNetwork Support for Drinking, Alcoholics Anonymous and Long-Term Matching Effects,â€ Addiction, 93(9), 1313-1333.
[29] Longabaugh, Richard, Martha Beattie, Nora Noel, Robert Stout, and Paul Malloy
(1993), â€œThe EÂ¤ect of Social Investment on Treatment Outcome,â€ Journal of Studies
on Alcohol, 54(4), 465-478.
[30] Longabaugh, Richard, Barbara McCrady, Ed Fink, Robert Stout, Thomas McAuley,
Cathy Doyle and Dwight McNeill (1983), â€œCost-EÂ¤ectiveness of Alcoholism Treatment
in Partial vs Inpatient Settings - six-month outcomes,â€ Journal of Studies on Alcohol,
44, No 6, 1049-1071.
[31] Lu, Mingshan and Thomas G. McGuire (2001), â€œThe Productivity of Outpatient Treatment for Substance Abuse,â€ Journal of Human Resources, forthcoming.
[32] Lu, Mingshan (1999), â€œSeparating the â€œTrue EÂ¤ectâ€ from â€œGamingâ€ in Incentive Based
Contracts in Health Care,â€ Journal of Economics and Management Strategy, 8, issue 3,
383-431.
[33] Machado, Matilde P. (2001), â€œDollars and Performance: Treating Alcohol Misuse in
Maine,â€ Journal of Health Economics, 20 (4), 645-672.
[34] Machado, Matilde P. (1998), â€œDollars and Performance: Cost-eÂ¤ectiveness of the Public
Provision of Substance Abuse Treatment in Maine,â€ Boston University Dissertation.

54
[35] Maitso, S. A., J. R. McKay, and G. J. Connors (1990), â€œSelf-Report Issues in substance
Abuse: state of the art and future directions,â€ Behavioral Assessment, 12, 117-134.
[36] Manski, Charles F. (1996), â€œLearning about Treatment EÂ¤ects from Experiments with
Random Assignment of Treatments,â€ Journal of Human Resources, 31 (4), 709-733.
[37] McKay, James R. (1996), â€œComments on Finney et al. â€œThe EÂ¤ectiveness of Inpatient
and Outpatient Treatment for Alcohol Abuse: the need to focus on mediators and
moderators of setting eÂ¤ects,â€ Addiction, 91(12), 1803-1820.
[38] McLellan, Thomas A., Teresa A. Hagan, Marvin Levine, Frank Gould, Kathleen Meyers, Mark Bencivengo, and Jack Durell (1998), â€œSupplemental Social Services Improve
Outcomes in Public Addiction Treatment,â€ Addiction, 93(10), 1489-1499.
[39] McLellan, A. Thomas, George E. Woody, David S. Metzger, Jim McKay, Jack Durell,
Arthur I. Alterman, Charles P. Oâ€™Brien (1997), â€œEvaluating the EÂ¤ectiveness of Addiction Treatments: reasonable expectations and appropriate comparisons,â€ in: Egertson,
Joel A, Daniel M. Fox, and Alan I. Leshner (Eds), Treating Drug Abusers EÂ¤ectively.
Milbank Memorial Fund and Blackwell Publishers 7-40.
[40] McLellan, A. Thomas, Grant R. Grissom, Peter Brill, Jack Durell, David S. Metzger,
Charles P. Oâ€™Brien (1993), â€œPrivate Substance Abuse Treatments: are some programs
more eÂ¤ective than others?,â€ Journal of Substance abuse Treatment, 10, 243-254.
[41] McLellan, A. Thomas, Isabelle O. Arndt, David S. Metzger, George E. Woody, Charles
P. Oâ€™Brien (1993), â€œThe EÂ¤ects of Psychosocial Services in Substance Abuse Treatment,â€ Journal of the American Medical Association, 269 (15), 1953-1959.

55
[42] McLellan, A. Thomas, L. Luborsky, C. P. Oâ€™Brien, and G. E. Woody (1980), â€œAn
Improved Evaluation Instrument for Substance Abuse Patients: the Addiction Severity
Index,â€ Journal of Nervous and Mental Disorders, 168, 26-33.
[43] Moos, Rudolph, John Finney, and Ruth C. Cronkite (1990), Alcoholism Treatment.
Oxford University Press.
[44] Olley, Steven and Ariel Pakes (1996), â€œThe Dynamics of Productivity in the Telecommunications Equipment Industry,â€ Econometrica, 64(6), 1263-1298.
[45] Roche, Ann M., Michael D. Parle, Joanne M. Stubbs, Wayne Hall and John Saunders
(1995), â€œManagement and treatment EÂ¢cacy of Drug and Alcohol Problems: what do
doctors believe?,â€ Addiction, 90, 1357-1366.
[46] Shen, Yujing (1998), â€œSelection Incentives in a Performance-Based Contracting System,â€
Boston University manuscript.
[47] Strohmetz, D. B., Alterman, A. I. and Walter, D. (1990), â€œSubject Selection Bias in
Alcoholics Volunteering for a Treatment Study,â€ Alcoholism: Clinical and Experimental
Research,14, 736-738.
[48] Tims, Frank M., Bennett W. Fletcher, and Robert L. Hubbard (1991), â€œTreatment
Outcomes for Drug Abuse Clients,â€ in: Pickens, C.G., C. G. Leukefeld, and C. R.
Schuster (Eds), National Institute on Drug Abuse Research Monograph 106. Rockville,
MD: US Department of Health and Human Services.
[49] Walsh, Diana Chapman, Ralph Hingson, Daniel Merrigan, Suzette Morelock Levenson,
Adrienne Cupples, Timothy Heeren, Gerald CoÂ¤man, Charles Becker, Thomas Barker,

56
Susan Hamilton, Thomas G. McGuire, Cecil Kelly (1991), â€œA Randomized Trial of
Treatment Options for Alcohol-Abusing Workers,â€ The New England Journal of Medicine, September 12, 325 (11), 775-782.

57
Frequency of use parameters
cutoÂ¤s
error terms
lower
upper standard deviation correlation
3:0049
0:5781
Â¡3:4309 0:7787
(0:1436) (0:1045)
(0:0915)
(0:0304)
Table 14: Estimated frequency of use model

A

Appendix

A.1

Other estimated parameters

Our estimated model contains a large number of coeÂ¢cients in addition to the estimated treatment
and population eÂ¤ects discussed in the text. We begin with the frequency of use model, i.e. the
ordered probit model relating current health and frequency of alcohol use. Recall that we have
deâ€¦ned a categorical variable taking on three possible values to describe frequency of use. Thus,
we estimate two cut-oÂ¤ values. We also estimate the joint distribution of the error terms.60 The
estimates are presented in Table 14.
According to the estimates, a patient is using alcohol at least once a day if hi0 + Â´ i < Â¡3:4309,
and is abstinent if hi0 + Â´ i > 0:7787. A similar interpretation applies for frequency of use upon

Â¹ i + Â¹Ì : The standard errors of the estimates
completion, for which the relevant latent variable is h
i
are in parentheses, and indicate that our estimates for this frequency of use model are reasonably
precise. The relatively large variances on the error terms (relative to the distance between the
cutoÂ¤s) indicate signiâ€¦cant heterogeneity in the population of patients regarding the relationship
between health status and alcohol use. The fact that much of this variance is idiosyncratic (i.e. the
correlation coeÂ¢cient between the error term at the start of treatment and the error term at the
60

The coeÂ¢cient on h is set to equal to unity. This normalization deâ€¦nes the units of our latent
variable determining frequency.

58
end of treatment is only 0.58) suggests that the variable â€œreduction in frequency of useâ€ may not,
by itself, be a very precise outcome measure for patients.
We next turn to the eÂ¤ect of patient characteristics (X ) on the treatment process.

These

parameter estimates are collected in Table 15. Standard errors are in parentheses. The columns
present the estimated coeÂ¢cients on Xi in 1) initial health (h0 ), 2) the drift of the treatment process
(Â¹), 3) health at completion (h), 4) the probability of dropping out of treatment (Â¸), and 5) the
units equation (ln(u)). These coeÂ¢cients require cautious interpretations, as they incorporate both
the direct eÂ¤ect of the observable characteristic and an indirect eÂ¤ect through the conditional mean
of the unobservable characteristic. The two eÂ¤ects are not identiâ€¦ed separately. Recognizing this
ambiguity, the estimates have straightforward interpretations. For example, positive coeÂ¢cients in
the Â¹ equation indicate a better response to treatment. Positive coeÂ¢cients in the equations for h0
and h also indicate that the patient consumes alcohol less frequently at admission and completion.
Positive coeÂ¢cients in the equation for h and negatives coeÂ¢cients in the equations for h0 , Â¹, and

Â¸ indicate that the patient is likely to remain in treatment longer.61
We include in patient characteristics the date of admission as well as quarterly dummies.62 The
admission date captures time trends in the data, while the quarterly dummies allow for seasonal
o
More precisely hÂ¡h
is the mean time to completion, conditional on completion. Therefore the
Â¹
eÂ¤ect of a given variable x in the expected time to completion (conditional on completion) of the
average patient is given by the following expression:

61

d

Â³

hÂ¡ho
Â¹

dx

Â´

=

d(hÂ¡ho )
Â¹ Â¡ dÂ¹
dx
dx
Â¹2

Â¡
Â¢
h Â¡ ho

Â¢
Â¡
where Â¹ and h Â¡ ho take the values 0:1722 and 5: 3318 (= 5:9493 Â¡ 0:6175) for the average patient
in the sample (see Table 8).
62
In the estimation, all non-categorical variables are normalized to have mean zero and variance
one. For example, to convert the coeÂ¢cients on admission date into coeÂ¢cients on date measured
in days we need to divide by the standard deviation of the admission date variable, e.g. the time
trend in the drift equation is 0:0028
394 Â¼ 0:000007 per day.

59

Variable Description
Date of Admission
Males
Age
White
Married
Severity=Casual
Severity=Involved
Severity=Undetermined
Income if Stated
Income
undetermined
OSA Primary Payer
Self Primary Payer
Medicaid or Medicare
Primary Payer
Own Private Insurance
Primary Payer
Infrequent problems at
job at admission
Occasional problems at
job at admission
Frequent problems at
job at admission
Probation/Parole
or Furloughed
Drunk driving
Concurrent Psychiatric Problems
2nd Quarter
3rd Quarter
4thQuarter
Unemployed (and
not a student)
Unobserved
Characteristic

h0
Â¡0:1677
(0:0493)
Â¡0:1497
(0:1215)
Â¡0:0288
(0:0481)
Â¡0:0508
(0:1255)
Â¡0:0399
(0:1178)
0:9098
(0:1416)
0:2604
(0:1099)
0:0590
(0:1170)
Â¡0:0900
(0:0518)
Â¡0:1452
(0:1275)
0:4966
(0:1384)
0:1516
(0:1302)
0:0333
(0:1414)
Â¡0:0374
(0:1558)
Â¡1:7527
(0:1425)
Â¡2:0174
(0:2344)
Â¡3:0150
(0:3102)
1:3614
(0:1210)
0:8835
(0:1116)
Â¡0:0429
(0:1356)
0:2002
(0:1122)
0:2525
(0:1113)
0:2781
(0:1133)
Â¡0:0733
(0:0956)
1
Â¡

Â¹
0:0028
(0:0041)
Â¡0:0519
(0:0101)
0:0041
(0:0036)
Â¡0:0336
(0:0204)
0:0210
(0:0088)
0:0640
(0:0181)
0:0353
(0:0096)
0:0381
(0:0124)
Â¡0:0024
(0:0040)
Â¡0:0189
(0:0107)
0:2095
(0:0184)
0:2389
(0:0170)
0:1721
(0:0169)
0:2287
(0:0186)
0:0028
(0:0151)
Â¡0:0137
(0:0290)
Â¡0:0459
(0:0313)
0:0405
(0:0112)
0:1366
(0:0173)
Â¡0:0505
(0:0119)
Â¡0:0136
(0:0105)
Â¡0:0021
(0:0093)
Â¡0:0083
(0:0089)
Â¡0:0027
(0:0085)
Â¡0:0235
(0:0234)

h
Â¡0:2307
(0:0676)
Â¡0:1168
(0:1747)
0:0715
(0:0623)
Â¡1:0415
(0:1416)
0:2055
(0:1619)
Â¡0:1016
(0:1688)
0:1023
(0:1611)
Â¡0:3240
(0:1686)
Â¡0:1838
(0:0741)
Â¡0:2266
(0:1901)
1:1723
(0:2027)
0:5517
(0:1412)
1:2568
(0:1773)
0:7677
(0:1901)
Â¡1:3011
(0:2431)
Â¡2:1575
(0:3101)
Â¡2:7822
(0:3931)
1:6964
(0:2038)
0:7651
(0:1548)
Â¡0:1383
(0:2320)
0:1224
(0:1636)
0:1058
(0:1614)
0:2900
(0:1688)
Â¡0:1299
(0:1809)
Â¡0:8535
(0:0989)

Â¸
0:0429
(0:0242)
0:1628
(0:0558)
Â¡0:1660
(0:0280)
Â¡0:3077
(0:1514)
0:0361
(0:0557)
Â¡0:6815
(0:1166)
Â¡0:3711
(0:0609)
Â¡0:1622
(0:0646)
Â¡0:1140
(0:0288)
0:0755
(0:0695)
1:3428
(0:1379)
1:3299
(0:1300)
1:1955
(0:1296)
1:1413
(0:1341)
0:2117
(0:1060)
0:5577
(0:1523)
0:5018
(0:1316)
Â¡0:3913
(0:0617)
Â¡1:2203
(0:0961)
0:0842
(0:0721)
0:1208
(0:0666)
0:0807
(0:0718)
0:2235
(0:0637)
0:1580
(0:0480)
Â¡0:9248
(0:1200)

ln(u)
Â¡0:0458
(0:0122)
Â¡0:0134
(0:0291)
0:0619
(0:0113)
0:0913
(0:0796)
Â¡0:0250
(0:0273)
0:0048
(0:0400)
0:0777
(0:0257)
Â¡0:0396
(0:0315)
0:0364
(0:0130)
Â¡0:0350
(0:0344)
Â¡0:1163
(0:0721)
Â¡0:2661
(0:0689)
0:0796
(0:0692)
Â¡0:0460
(0:0684)
Â¡0:0861
(0:0487)
Â¡0:2716
(0:0719)
Â¡0:1858
(0:0742)
0:0884
(0:0273)
0:2269
(0:0272)
Â¡0:0080
(0:0422)
Â¡0:0315
(0:0356)
Â¡0:0049
(0:0323)
Â¡0:1054
(0:0303)
Â¡0:0445
(0:0249)
0:2616
(0:0486)

Table 15: CoeÂ¢cient estimates for patient characteristics (X). Bootstrap standard errors in
parentheses

60
eÂ¤ects. The time trend in Â¹ is not signiâ€¦cantly diÂ¤erent than zero over the sample period, perhaps
indicating that the improvement in the technology or an improvement in incentives to provide
eÂ¤ective treatment was minor.63 Over time patients became more likely to drop out, and were less
likely to be abstinent at completion. For the most part, the quarterly eÂ¤ects are not very signiâ€¦cant.
There is nothing particularly remarkable about the coeÂ¢cients on the basic demographic variables. The sex of the patient matters, in that males, all else equal, respond worse to treatment and
are more likely to dropout of treatment prematurely. Married patients do better in treatment, and
older patients are less likely to dropout. Higher income patients are less likely to dropout and are
less likely to be abstinent upon completion. Patients who are unemployed at admission are more
likely to leave treatment prematurely.
Legal involvement matters signiâ€¦cantly. Patients on parole or pending trial, or in treatment
due to a drunk-driving oÂ¤ense, respond better to treatment, are more likely to be abstinent upon
completion, and are less likely to drop out of treatment. These pluses could be due to the incentives
associated with their legal involvement. Payment source matters in various ways. Not surprisingly,
for example, patients paying out of pocket respond better to treatment than the others and receive
less units of treatment.
The initial severity of the substance abuse problem impacts the treatment process in several
ways. As expected, severity is a strong predictor of initial health. Dependent/dysfunctional alcohol
abusers (the omitted category) do not respond as well to treatment as casual or involved users. Patients who enter treatment with problems on the job related to alcohol abuse respond to treatment
63

For the same increase in health, the point estimate of the time trend in the drift equation
implies that the average patient admitted in October 1992 would have completed treatment about
1.5 % faster if admitted a year later. OSA introduced â€œperformance based contractingâ€ over the
sample period, using the information collected in MATS in its budget allocation decisions. It is
possible that this change in information structure altered incentives. See Commons, McGuire and
Riordan (1997).

61
Â¾
0:7117
(0:0280)

Â°3
Â¡0:0117
(0:0021)

Â°4
0:8010
(0:2230)

Â°5
0:8874
(0:0803)

Table 16: Other estimated CoeÂ¢cients
similarly to other patients (no problems on the job is the omitted category), but are less likely to
be abstinent on completion and are more likely to exit treatment prematurely.
The last row of Table 15 contains estimated coeÂ¢cients on the unobservable patient characteristic "i . The coeÂ¢cient is normalized to 1 for the hi0 equation (this deâ€¦nes the units health is
measured in). The unobserved patient characteristic is particularly important in the completion
threshold, dropout, and units equations.
Other miscellaneous coeÂ¢cients estimated are the variance of the Wiener process and the time
dependent coeÂ¢cients in the attrition model. These are reported in Table 16.

Attrition, for

example, is discretely higher in the â€¦rst week and nearly constant thereafter, as we expected from
the sample attrition histogram in Figure 3.

A.2

Estimated productivities for other patient populations

Table 17 reports productivities for every patient population in every agency using health as the
output measure and controlling for both unobservable and observable characteristics of patient
populations.

A.3

Abstinence as an output measure

An alternative measure of output is the expected number of discharged abstinent patients in a
treated population. To compute this quantity, we determine distributions of â€¦nal health status for

62

All
1
P

2

O

3

P

4

U

5

L

6

A

7

T

8

I

9

O

10

N

11
12
13
14
15

AG EN CY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
10:96
14:95
9:33
8:36
8:45
8:71
8:09
7:55
6:27
5:67
10:17
8:17
6:61
7:59
7:87
(0:84) (1:35) (0:90) (1:05) (1:22) (0:89) (0:54) (0:54) (0:85) (0:75) (1:56) (0:94) (0:69) (1:05) (1:32)
12:87
16:74
9:35
9:97
10:73
9:75
8:81
8:32
7:75
7:23
10:17
9:68
7:13
8:52
7:92
(0:90) (1:69) (1:29) (1:30) (1:87) (1:21) (0:78) (0:76) (1:03) (0:87) (2:07) (1:14) (0:86) (1:22) (1:83)
9:07
12:08
5:80
6:20
5:09
4:62
4:26
4:24
4:25
3:94
4:47
3:89
3:21
3:19
2:35
(1:08) (1:48) (1:27) (1:56) (2:09) (1:29) (0:98) (0:90) (1:34) (0:94) (2:22) (1:37) (1:05) (1:49) (1:98)
8:03
12:16
8:38
5:75
5:10
6:41
6:23
5:86
3:88
3:30
8:87
5:30
5:35
5:63
6:72
(1:13) (1:38) (0:59) (1:05) (1:14) (0:92) (0:74) (0:70) (0:96) (0:89) (1:19) (1:32) (0:78) (1:17) (0:94)
12:43
16:03
8:75
9:45
9:75
8:87
8:03
7:59
7:24
6:76
9:12
8:66
6:36
7:49
6:84
(1:10) (1:85) (1:49) (1:52) (1:99) (1:55) (1:03) (1:06) (1:19) (0:93) (2:34) (1:51) (1:07) (1:45) (2:06)
13:29
17:93
11:94
10:47
10:94
11:43
10:60
9:74
8:01
7:22
13:37
10:87
8:59
10:05
10:61
(1:36) (1:92) (1:29) (1:42) (1:45) (1:53) (1:00) (0:99) (1:15) (1:08) (2:19) (1:39) (0:95) (1:48) (1:78)
10:66
14:93
10:10
8:17
8:06
9:10
8:57
7:87
6:04
5:35
11:29
8:33
7:02
7:98
8:85
(1:04) (1:48) (0:84) (1:09) (1:19) (0:65) (0:65) (0:67) (0:97) (0:99) (1:34) (1:18) (0:73) (1:19) (1:18)
12:29
16:34
10:14
9:66
10:21
10:20
9:34
8:67
7:47
6:82
11:38
9:92
7:56
8:98
9:01
(0:87) (1:51) (1:05) (1:12) (1:35) (1:03) (0:59) (0:63) (0:88) (0:76) (1:74) (0:99) (0:72) (1:07) (1:47)
11:53
15:50
9:56
8:87
8:92
9:21
8:51
7:90
6:70
6:08
10:44
8:74
6:83
7:94
8:04
(0:97) (1:49) (0:97) (1:19) (1:45) (1:06) (0:70) (0:53) (0:96) (0:84) (1:72) (1:06) (0:79) (1:15) (1:50)
14:22
17:89
9:31
11:09
12:56
10:36
9:21
8:79
8:84
8:43
10:13
10:66
7:44
9:11
7:95
(1:23) (2:30) (1:71) (1:52) (2:33) (1:64) (1:16) (1:17) (1:14) (0:93) (2:58) (1:51) (1:17) (1:52) (2:29)
12:28
15:23
7:46
9:38
10:26
8:26
7:31
7:02
7:40
7:12
7:76
8:46
5:78
7:03
5:84
(1:13) (2:15) (1:56) (1:46) (2:54) (1:63) (1:09) (1:09) (1:14) (0:73) (2:38) (1:45) (1:08) (1:51) (2:14)
7:96
12:18
9:22
5:83
5:29
7:04
6:90
6:35
3:98
3:35
10:30
5:85
5:95
6:33
8:15
(1:42) (1:74) (0:92) (1:23) (1:45) (1:38) (1:02) (0:98) (1:12) (1:10) (1:25) (1:60) (0:90) (1:35) (1:13)
13:01
17:25
10:14
10:09
10:84
10:19
9:29
8:75
7:78
7:18
11:08
9:96
7:60
8:99
8:69
(1:10) (1:71) (1:26) (1:32) (1:55) (1:25) (0:81) (0:81) (1:04) (0:92) (2:10) (0:94) (0:85) (1:29) (1:77)
10:71
14:24
8:36
8:00
7:65
7:71
7:13
6:67
5:91
5:40
8:57
7:13
5:62
6:35
6:28
(0:99) (1:54) (1:15) (1:35) (1:64) (1:24) (0:80) (0:80) (1:06) (0:90) (1:92) (1:13) (0:81) (1:24) (1:66)
12:84
16:74
9:64
10:04
10:81
10:09
9:14
8:58
7:83
7:26
10:68
10:03
7:39
8:87
8:40
(1:04) (1:65) (1:20) (1:25) (1:70) (1:12) (0:74) (0:71) (1:07) (0:89) (1:97) (1:09) (0:82) (1:23) (1:70)
6:99
11:04
8:15
4:87
4:15
5:63
5:61
5:28
3:14
2:60
8:66
4:38
4:98
5:04
6:69
(1:14) (1:60) (0:90) (1:03) (1:14) (1:10) (0:85) (0:88) (0:90) (0:87) (1:28) (1:35) (0:77) (1:22) (0:78)

Table 17: Estimated Productivities in terms of health
each individual in the population. More precisely, for a given â€¦nal health status, we compute the
probability of abstinence conditional on this health status. For completors this is fairly easy, as we

b

estimate the completion threshold, hij . For dropouts the calculation is a bit harder because there is
a probability distribution over the â€¦nal health status of patients. To compute expected abstinence,
we simulate from this distribution and average the abstinence probability over the simulation draws.
Table 18 reproduces the productivity comparisons of Table 11 using abstinence, instead of aggregate health improvement, as the measure of output. The productivity rankings using abstinence
appear very diÂ¤erent. In fact, the correlation coeÂ¢cient between the two sets of productivities is
only 0.31.64 As the productivity numbers in this table are literally the number of abstinent patients
per dollar spent, it appears that the agencies in Maine are producing between 2.5 and 5.0 abstinent
64

The low correlation between productivities using health improvement and abstinence reported in
Tables 11 and 18 may be related to the diÂ¤erent assumptions involved regarding the counterfactuals.
Assuming that untreated patient receive no health improvement may be a dramatically diÂ¤erent
assumption than assuming that they are all non-abstinent. However, the following policy analyses
show that conclusions regarding good and poor performing agencies are fairly insensitive to the
output measure used.

63

7300
2

7250

1

Expected Number of Abstinent Patients

7200

7150

4

3

7100

9
7050

5
6

10

8

7

7000

13

12
11

6950

14

6900

15

6850
1000000

1500000

2000000

2500000

3000000

3500000

Total Costs of Treatment

Figure 8: Expected number of abstinent patients versus costs

patients per $1000. This calculation leaves aside the question of how many of these patients would
have been abstinent in the absence of any treatment.
Figure 8 repeats the analysis of Figure 7 using abstinence at discharge, rather than health
improvement, as the relevant measure of output.

The results are similar.

In this case, the

agencies that are potentially on the eÂ¢ciency frontier are Agencies 2, 4, 5, 6, and 12. Agencies 13
and 10 still appear to be very ineÂ¢cient.
Using bootstrap methods, we test as before whether an agency is on the eÂ¢ciency frontier.
Table 19 reports results for both abstinence and health improvement.

Using abstinence as the

output measure, Agencies 3, 8, 10, 13, and 15 can be rejected as eÂ¢cient with 95% conâ€¦dence, 9
and 14 can be rejected with 90% conâ€¦dence. It seems clear that regardless of the outcome variable

64

Own population
Agency

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

product.

0:0036
(0:0002)
0:0032
(0:0004)
0:0024
(0:0001)
0:0036
(0:0004)
0:0037
(0:0005)
0:0039
(0:0002)
0:0038
(0:0002)
0:0030
(0:0001)
0:0037
(0:0004)
0:0031
(0:0002)
0:0032
(0:0003)
0:0050
(0:0004)
0:0024
(0:0002)
0:0038
(0:0003)
0:0025
(0:0002)

ranking

8
9
14
7
5
2
3
12
6
11
10
1
15
4
13

Entire population
NOT accounting for pop. eÂ¤.
product.
ranking

Entire population
accounting for pop. eÂ¤.
product.
ranking

0:0034
(0:0001)
0:0031
(0:0003)
0:0023
(0:0001)
0:0036
(0:0003)
0:0039
(0:0003)
0:0039
(0:0002)
0:0039
(0:0001)
0:0030
(0:0001)
0:0035
(0:0003)
0:0032
(0:0002)
0:0032
(0:0002)
0:0048
(0:0003)
0:0026
(0:0002)
0:0037
(0:0002)
0:0025
(0:0002)

0:0030
(0:0002)
0:0031
(0:0003)
0:0029
(0:0002)
0:0031
(0:0003)
0:0036
(0:0004)
0:0042
(0:0002)
0:0037
(0:0002)
0:0030
(0:0001)
0:0028
(0:0003)
0:0025
(0:0002)
0:0040
(0:0004)
0:0045
(0:0004)
0:0024
(0:0002)
0:0034
(0:0003)
0:0032
(0:0003)

8
11
15
6
4
3
2
12
7
10
9
1
13
5
14

10
8
12
9
5
2
4
11
13
14
3
1
15
6
7

Table 18: Agency productivity rankings using abstinence as an output measure

65

Agency
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Abstinence
Estimate Probability
0
0.747
1
0.883
0
0.026*
1
0.390
1
0.546
1
0.760
0
0.429
0
0.039*
0
0.078
0
0.013*
0
0.383
1
0.870
0
0.000*
0
0.0649
0
0.007*

Health improvement
Estimate Probability
0
0.468
1
1.000*
0
0.169
1
0.201
0
0.442
1
0.708
0
0.299
0
0.039*
0
0.000*
0
0.000*
1
0.870
1
0.740
0
0.000*
0
0.117
0
0.130

Table 19: Statistical tests of being on the eÂ¢ciency frontier in terms of abstinence
used, Agencies 8, 9, 10 and 13 are underperformers.

A.4

Substance abuse treatment literature

We discuss how our work relates to the literature on substance abuse treatment. The received
literature focuses on four questions: Is treatment eÂ¤ective? Are all treatment programs equally
eÂ¤ective? Why do programs diÂ¤er in their eÂ¤ectiveness? Which treatments are more cost eÂ¤ective?

A.4.1

Is treatment eÂ¤ective?

This question begs for a deâ€¦nition of eÂ¤ectiveness. McLellan et al. (1997) identiâ€¦es three dimensions of eÂ¤ectiveness: 1) reduction of alcohol or drug use; 2) improvement in personal and social
functioning; and 3) improvements in public health, and conclude that the weight of the evidence
supports the conclusion that treatment is eÂ¤ective in each dimension. Our study does not directly

66
address the eÂ¤ectiveness of treatment because our sample does not include alcohol abusers who do
not receive treatment. However, our conclusion that some programs are more eÂ¤ective at reducing
alcohol use than others (Table 6) certainly does suggest that the treatment provided by the better
agencies is eÂ¤ective. To think that treatment is ineÂ¤ective would seem to require a conclusion that
the treatment provided by the other agencies is counterproductive.
Recent research views substance abuse treatment as a multi-product activity. Accordingly,
McLellan et al. (1980) has proposed an Addiction Severity Index (ASI) composed of seven distinct
categories of outcome measures: employment; medical status; alcohol use; drug use; legal status;
family and social relationships and psychiatric symptoms.65 Recognizing this perspective, OSA
designed MATS in order to recover multiple outcomes to evaluate programs (i.e. abstinence, reduction in use, employability, job improvement, problems at job/school, problems with signiâ€¦cant
other/family, problems with the law and the judicial system, etc.).66
A strength of our methodology is that it utilizes the information contained in multiple outcome
measures to estimate a production process and compare productivities. In addition to reduction
65

The interdependence of these diÂ¤erent categories of health improvement is still not well understood. For example JaÂ¤e (1984) discusses the independence of these indicators in the short
run, while Moos, Finney and Cronkite (1990) found that improvements in any one category are
correlated with improvements in the other categories.
66
MATS data is based on agency assessments of patients at admission and discharge from treatment. Some of this data are therefore self-reported measures. MATS data was collected in order
to implement performance based contracting (PBC). Lu (1999) argued that agencies changed reporting practices after the introduction of PBC in â€¦scal year 1993. The broader substance abuse
treatment literature has also questioned the reliability of self-reported data (e.g. McLellan et al
(1997), Ball and Ross (1991), Long et al. (1998), Butler et. al (1987), Moos, Finney and Cronkite
(1990), Maitso et. al (1990), Aitken (1986), Aplser and Harding 1991)). We would not expect
this to be a problem if reporting biases in our outcome variables were not correlated with agency
assignments.
The timing of measurement of our variables is also potentially problematic. MATS measures variables at admission into treatment and at discharge. Aplser and Harding (1991) criticize measures
at discharge because they may not reâ€¡ect the long lasting eÂ¤ects of treatment. On the other hand
a long follow-up period has the problem of distinguishing between the eÂ¤ects of several treatment
episodes. They also argue that measurement at admission time may be biased because of the â€œhit
the bottomâ€ eÂ¤ect, but this criticism only matters for our study if this eÂ¤ect varies across agencies.

67
in use,67 our approach gives weight to treatment outcomes which OSA did not highlight, including time in treatment, and discharge status. We postulate an underlying latent measure of a
patientâ€™s health, and view multiple outcome measures as containing diÂ¤erent information about
improvements in a patientâ€™s underlying health. In contrast to the ASI, which gives â€¦xed weights
to clinically important outcome measures, our structural model implicitly weights the importance
of these measures according to their information content as revealed by the data.
Moreover, in principle we could extend our methodology to include additional outcome measures
contained in our data set that we have not exploited yet. For example, our study includes â€œproblems
on the jobâ€ at admission as a patient characteristic (included in X ). We could also use discharge
data to include reductions in problems on the job as an outcome measure similarly to how we
analyze reduction in frequency of use. Presumably this extension would increase the accuracy
of our estimates or allow a richer model, although these gains would come at a cost of greater
computational complexity.68

A.4.2

Are all treatment programs equally eÂ¤ective?

The relative performance of substance abuse treatment programs is controversial. Emrick (1975)
argues that the literature does not support the conclusion that programs are diÂ¤erent in their performance. However, the more recent literature repeatedly observes that substance abuse treatment
programs diÂ¤er in their eÂ¤ectiveness (McLellan et al. (1997), McLellan et al. (1993), Ball and Ross
(1991), Anglin and Hser (1990) among others). For example, McLellan et al. (1993) â€¦nd signiâ€¦cant
diÂ¤erences in the nature and eÂ¤ectiveness of treatments for four otherwise similar private programs,
67

We consider frequency of use information at discharge only for patients who complete treatment.
At the cost of some computational complexity, we could also consider frequency of use data for
patients who leave treatment prematurely.
68
See foonotes 10, 11 and 12.

68
and suggest that such diÂ¤erences are likely to be even more pronounced for publicly funded programs with unstable funding. Our comparison of the â€¦fteen largest publicly funded outpatient
programs in Maine conâ€¦rms that the performance of these agencies diÂ¤er even after controlling for
observable and unobservable patient population characteristics (Table 17).69

A.4.3

Why do programs diÂ¤er?

Some recent work in the substance abuse treatment literature tries to open the â€œblack boxâ€ of
treatment and identify its â€œactive ingredientsâ€ (McLellan et al. (1993), McLellan et al. (1998),
Ball and Ross (1991), Finney et. al (1996), Moos, Finney and Cronkite (1990)). In contrast, most of
the â€œblack boxâ€ literature relies on patient characteristics as the main predictors of diÂ¤erences across
programs. Characteristics such as less severity of dependence, intact marriage, lower psychiatric
symptoms, job, less family problems, minimal criminal activity, are associated with better outcomes
(McLellan et al. (1997), Apsler and Harding (1991), Anglin and Hser (1990)). Our results conform
with this literature in that we control extensively for patient characteristics. However, we go further
and identify agency â€¦xed eÂ¤ects as an important determinant of treatment eÂ¤ectiveness.
In their search for the active ingredients of treatment, researchers devoted themselves to the
acquisition of very detailed data sets with information on all aspects of the treatment scenario.
69

Our treatment of unobserved characteristics solves a sample selection problem inherent in nonrandomized data, i.e. diÂ¤erent agencies having populations with diÂ¤erent unobservable characteristics. Sample selection problems are intrinsic to â€¦eld studies, and a failure to deal with this
adequately is often the basis of criticism (e.g. McClellan (1997)): In the context of our setting,
Shen (1998) argued that the introduction of performance based contracting induced agencies to
admit patients more selectively. Of course, even randomized trials can suÂ¤er from sample selection
problems (e.g. Heckman and Smith (1995); Strohmetz, Alterman and Walter (1990)). Patient
attrition creates a second selection problem in our data, we deal with it by explicitly modelling
a patient attrition process. The received literature has also recognized the importance of patient
attrition in evaluating outcomes (e.g. Apsler and Harding (1991), Anglin and Hser (1990), Ball
and Ross (1991), Gerstein and Hardwood (1990)).

69
Ball and Ross (1991) exhaustive study of six methadone treatment programs, found that leadership, organization, staÂ¢ng patterns, amount of services to patients were among the variables that
accounted for a signiâ€¦cant proportion of the variance across programs. Similarly, Joe, Simpson and
Sells (1994) found evidence that both the type of the admission staÂ¤ and the staÂ¤ responsible for
the treatment plan mattered for the patient relapse rates. Moos, Finney and Cronkite (1990) consider subjective indicators of treatment quality from patients and staÂ¤ that measure variables such
as support, relationship between staÂ¤ and patients, organization of the program, etc. Our agency
â€¦xed eÂ¤ects can be interpreted as capturing these diÂ¤erences. Our conclusion that superior performance is idiosyncratic is consistent with Ball and Rossâ€™ (1991) statement regarding Methadone
treatment programs: â€œEach clinic develops its own philosophy of treatment which appears to be
strongly conditioned by the directorâ€™s personal philosophy,â€ which they found was important to
explain some diÂ¤erences in performance.
The type and quantity of treatment services have been associated with diÂ¤erences in outcomes
across programs (McLellan et al. (1993), McLellan et al (JAMA 1993)). For example, Moos,
Finney and Cronkite (1990) use treatment intensity as an explanatory variable of outcomes in their
analysis of â€¦ve residential programs for alcoholics.70 Lu and McGuire (2001), using a diÂ¤erent
sample of MATS data, found a positive and signiâ€¦cant eÂ¤ect of more units of treatment for the
more severe substance abusers although this eÂ¤ect disappears when they control for the interaction
of â€œunits of treatmentâ€ and â€œtime in treatment.â€71 Time in treatment is sometimes used as a proxy

70

See also Finney, Hanh and Moos (1996) where they review the studies comparing outpatient
and inpatient programs (which diÂ¤er in intensity), and Walsh et al. (1991) interesting study based
on randomized clinical trials where patients are assigned to three treatment modalities varying in
treatment intensity.
71
Other studies worth mentioning but where causality cannot be established due to endogeneity
are: Moos, Finney and Cronkite (1990) who show an association between higher participation in
some treatment components such as therapy sessions, AA meetings, â€¦lms, attendance to church
services, etc. and outcomes; and Ball and Ross (1991) who arrive to similar conclusions.

70
for services received under the assumption that longer stays yield a higher exposure to treatment
(Apsler 1991). The literature shows that patients who stay longer in treatment tend to do better
(McLellan et al. (1997), Longabaugh (1983), IOM report (1990), Tims et al. (1991), Ball and
Ross (1991), Moos, Finney and Cronkite (1990).72 ) Not all of the literature recognizes that time
in treatment is potentially endogenous in the sense that more diÂ¢cult patients might dropout of
treatment earlier (McLellan et al., 1997).73 Our analysis endogenizes time in treatment and patient
attrition within a structural model of the treatment process.
We do not have data on an individual patientâ€™s time path of treatment. However, we do
know the number of units of treatment provided in each treatment episode from which we can
compute the (average) intensity of treatment. A good direction for further research is to extend
our structural model by adding an equation that predicts intensity of treatment.74 We expect that
treatment intensity will impact the drift and may, in part, explain some of the observed diÂ¤erences
in productivity across agencies.

A.4.4

Which treatments are more cost eÂ¤ective?

Cost-eÂ¤ectiveness analyses of substance abuse treatment are fewer than treatment eÂ¤ectiveness
studies. Most studies on cost-eÂ¤ectiveness compare alternative treatment modalities (e.g. inpatient
vs. outpatient). Walsh et al. (1991), for example, â€¦nd that the ultimate treatment costs for
alcoholic patients receiving an initial three weeks of inpatient therapy followed by participation
72

There is a new trend analysing the eÂ¤ects of â€œbrief interventionsâ€ for alcoholics and a number
of studies claim their eÂ¤ectiveness as compared with longer treatment. Drummond (1997) criticizes
this new literature on the basis of sample selection.
73
An exception is French et al. (1991) who control for unobserved patient heterogeneity in their
study of the impact of time in treatment on labor market outcomes at a one year follow-up.
74
The dependence of average intensity on time in treatment allows for variable actual intensity
over a treatment episode. For example, patients might be more likely to miss appointments as time
goes on.

71
in an Alcoholics Anonymous (AA) group was only 10% more than for a comparison AA group
not receiving the initial inpatient treatment and performed somewhat better. Longabaugh et al.
(1983) showed that a partial hospital setting was substantially less costly than an extended inpatient
setting with no signiâ€¦cant diÂ¤erences in performance. Long et al. (1998) compared a â€¦ve week
inpatient program with a two week program followed by daily outpatient therapy concluding that
the shorter program reduced costs by 33% with no signiâ€¦cant diÂ¤erence in outcomes six to twelve
months later.75 Our study focuses solely on outpatient services and â€¦nds signiâ€¦cant diÂ¤erences in
cost-eÂ¤ectiveness of treatment agencies. We do not explore explicitly whether these diÂ¤erences are
due to diÂ¤erences in program design76 , or due to diÂ¤erences in eÂ¢ciency (e.g selection of better
clinicians.) This is a good topic for further research.
Machado (2001), using aggregate MATS data, found that agencies that spent more per patient
did not have better abstinence rates at discharge,77 suggesting that Maine could reduce expenditures
on publicly funded substance abuse treatment without compromising performance. Our more
detailed study of cost-eÂ¤ectiveness, using patient-level data, supports this suggestion and develops
a methodology for benchmarking treatment agencies and identifying which are more cost eÂ¤ective.
We conclude that Maine potentially could reduce spending on alcohol abuse treatment without
compromising the health outcomes of patients by identifying and transferring best practices (Tables
1 and 12).

75

The data came from a facility that revamped its program. The authors caution that the
performance results could be due to better staÂ¤ motivation in the revised program with a shorter
inpatient stay.
76
Treatment agencies provide diÂ¤erent kinds of outpatient services. In this paper we weight
â€œfamily therapy,â€ â€œindividual sessionsâ€ and â€œgroup sessionsâ€ according to their relative unit costs.
This approach implicitly allows group therapy to be more eÂ¤ective than individual therapy.
77
Machado (1998) expands her regression model to allow for heterogeneity in the use of funds
across agencies and â€¦nds evidence that OSA could gain by reallocating funds to at least one agency.
Her results, however, are not very powerful due to data aggregation and few observations per agency.

